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ABSTRACT 
Immunometabolism is fueling breakthroughs across oncology, infection control, and 
inflammation research. It is appreciated that CD8 T cells are important players in all of the 
above-mentioned fields. Access to metabolic nutrients is critical for an effective CD8 T cell 
immune response to infection. Other groups have successfully identified transporters for 
exogenous import of sugars and amino acids for CD8 T cells, however, there is still a knowledge 
gap for how CD8 T cells can actively transport exogenous fatty acids. Here, I propose the 
lysophosphatidylcholine (LPC) transporter, Major Facilitator Super Family Domain Containing 
2a (MFSD2A), is upregulated on activated CD8 T cells and is essential for memory T cell 
maintenance. MFSD2A deficiency in mice resulted in decreased import of LPC esterified to long 
chain fatty acids (LCFAs) into activated CD8 T cells, reduced memory T cell formation and 
maintenance, and reduced response to secondary infection. Import of LPCs was required to 
maintain T cell homeostatic turnover, that when lost resulted in a decreased memory T cell pool 
and therefore a reduced secondary response to secondary infection. I hypothesize that de novo 
fatty acid synthesis (FAS) is upregulated to compensate for loss of MFSD2A. These data were 
determined by using a thorough and multidisciplinary approach that combines the fields of 
immunology and human genetics. Importantly, there are families with known mutations in 
MFSD2A. These families have not been immunophenotyped for CD8 T cell dysregulation due to 
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loss of MFSD2A, but it is reasonable to suggest that they may suffer from a decreased response 
to infection. This project is relevant to public health because there is currently a knowledge gap 
in how exogenous lipid species imported by MFSD2A can affect the CD8 T cell immune 
response to infection, including how MFSD2A and LPC deliverables could be used for future 
immunotherapy targets. 
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1.0  BACKGROUND AND SIGNIFICANCE 
1.1 INTRODUCTION TO THE IMMUNE SYSTEM 
The immune system is a mix of both quick acting innate cells and slower but more 
specific adaptive immune cells that work together to keep the host clean of invading pathogen. 
Without one or the other, the body is not capable of fighting off foreign invaders such as 
bacterial or viral infections. Upon pathogen infection, the bacteria or virus will rapidly replicate 
and elicit an immune response. After pathogen entry at the barrier tissues, the innate immune 
response will be initiated by pattern recognition receptors (PRRs)[1]. Innate cell types like 
macrophages will engulf and destroy the pathogen as well as signal for other cells to join the 
immune system cascade to prevent the pathogen from further infecting the host[2]. Pathogen-
associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPS) 
along with the immune complement system will further strengthen immune signaling, 
recruitment, and inflammation to continue to ward off the invading microbe[3-6].  
An important component of this immune surveillance system is the dendritic cell (DC). 
Naïve DCs are constantly surveying the host in patrol of pathogen through PRRs. DCs are the 
only cell type that is capable of taking up self and non-self-antigen. Once internalized, these 
antigens are processed into proteolytic peptides and loaded onto major histocompatibility 
complex class I or class II (MHC I and MHC II) molecules[7]. DCs unique ability to take in 
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antigen, degrade it, and load it onto MHC complexes is called antigen presentation[8, 9]. Potent, 
mature DCs are known as antigen presenting cells (APCs) and are capable of activating adaptive 
immune cells by presenting peptide MHC[7]. In order to accomplish this, mature DCs need to 
travel through circulation, enter the peripheral lymph tissue, release various chemokines and 
signaling molecules, and eventually come in contact with naïve CD8 and CD4 T cells[6, 10, 11]. 
A summary of this is found in Figure 1, below. The remainder of this text will focus on the CD8 
T cell immune response to infection. 
 
Figure 1. Antigen presentation by DC and CD8 T cell activation 
An immune response to pathogen is initiated by DAMPs/PAMPs on PRRs on a dendritic cell (DC). The DC will 
take in antigen from the pathogen, degrade it, and load it onto MHC I complex in a process known as antigen 
presentation. The DC will migrate to the peripheral lymphoid tissue where it will encounter a naïve CD8 T cell. T 
cell activation is initiated by the T cell receptor (TCR) binding to MHC I on the antigen presenting cell (APC). The 
second required T cell activation stimulus is the co-stimulatory receptor CD28 binding to CD80 and CD86 on the 
APC. Cytokine signals like IL-12 and Type I interferon (IFN) released from the APC enhance CD8 T cell 
stimulation. 
CD28 
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1.2 INTRODUCTION TO THE CD8 T CELL IMMUNE RESPONSE 
CD8 T cells undergo conventional αβ T cell development in the thymus where they then 
migrate out into the periphery for constant immune surveillance[9, 12]. They will remain in a 
naïve, inactivated state until making contact with a unique glycoprotein peptide bound to MHC I. 
In order to become active, they require two stimuli[9, 13-15]. The first being the cell’s T cell 
receptor (TCR) binding to MHC I. The second required stimulus is the co-stimulus surface 
receptor CD28 on the T cell binding to CD80 CD86 on an APC, usually a dendritic cell. This co-
stimulus can be enhanced or replaced by certain cytokines, including IL-12 and Type I interferon 
(IFNα/β) [13, 14, 16].  T cell activation is illustrated in Figure 1. An example of CD8 T cell 
activation is OVA-albumin peptide binding to the MHC I receptor on an APC and being 
presented to the TCR of the CD8 T cell, initiating an adaptive immune response and cytotoxic 
activities of the CD8 T cell. After T cell activation, the newly activated effector CD8 T will 
undergo rapid clonal expansion and release both inflammatory and cytotoxic molecules to assist 
in pathogen killing such as IFNγ[14, 15, 17]. Importantly, IL-2 release will be critical for CD8 T 
effector cell formation and function and may play a role in determination of memory cell fate[18, 
19]. Once pathogen is cleared from the system, the majority of these clonal specific CD8 T cells 
will undergo a contraction phase of programmed cell death in the form of apoptosis. A small 
portion of these cells will maintain for years as memory CD8 T cells. A summary of this CD8 T 
cell response to pathogen can be found in Figure 2. 
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Figure 2 The CD8 T cell immune response to pathogen 
 
The adaptive immune response to infection kicks in days after infection whenever a naïve CD8 T cell encounters 
peptide MHC on an antigen presenting cell (APC). Activated T cells will undergo a rapid clonal specific 
proliferative burst accompanied by inflammatory cytokine production, peaking at day 7 post-infection (pi). Most 
cells will contract and die via apoptosis however some will go on to be maintained as memory T cells, enable to 
quickly respond to recurrent antigen exposure. 
 
1.2.1 MEMORY CD8 T CELL PHENOTYPING: A CLOSER LOOK 
Memory CD8 T cells are a unique and important variety of CD8 T cells as they are able 
to provide a quicker and more robust clonal expansion response relative to naïve CD8 T cells if 
the body comes into contact with a secondary infection with the same pathogen[20, 21]. This 
idea of immunological memory is a critical component to vaccine development[22-27]. 
Traditional vaccines make use of generating protective antibodies, however newer approaches 
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have focused on using CD8 T memory cells – HIV and tumor vaccines included[28-30]. For the 
most part, memory CD8 T cells can be classified by a classical phenotypic signature based on 
cell surface marker expression, which will be discussed in this work under the next subtopic. In 
addition to surface marker classification, murine memory CD8 T cells can be more broadly 
classified as central memory, effector memory, and tissue resident memory based on location 
within the body[31]. The predominant subtype is known as central memory CD8 T cells (Tcm). 
Tcm are long-lived memory CD8 T cells that home to the secondary lymphoid tissue and provide 
a rapid, frontline defense upon secondary infection. Once restimulated, these Tcm are capable of 
producing a robust recall response to at the site of infection. These cells are phenotyped as 
CD44hiCD62LhiKLRG1loCD127hi[13, 32-34]. The second subtype of memory CD8 T cells are 
effector memory CD8 T cells (Tem). Tems are found in the circulation between lymphoid tissues 
and are known to be superior producers of effector cytokines upon restimulation[33, 34]. They 
are usually phenotyped as being CD44hiCD62LloKLRG1hiCD127lo cells. The third type of 
memory CD8 T cells in mouse is the tissue-resident (Trm) memory CD8 T cells. Trms are 
noteworthy for being a top-line immune defender in non-lymphoid, common barrier tissues such 
as the skin, lung, gut, and adipose[35]. Trms have a characteristic surface marker phenotype of 
being CD69hi and (usually) CD103hi in addition to being CD44hiKLRG1loESLmod[35, 36].  
My thesis will focus primarily on central memory CD8 T cells, or those that are found 
within lymphoid tissue. There is currently a large gap in the knowledge of what determinants 
make a Teff become a Tmem. It has been accepted in the field that memory CD8 T cells typically 
are those cells that are IL-2 producing effector CD8 T cells and that they are regulated by mTOR 
transcription[37], however, there is still much to be elucidated about memory CD8 T cell 
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development and what signaling, metabolic, genetic, and epigenetic changes may lead to this cell 
fate[9, 15, 31, 38].  
1.2.2 LISTERIA MONOCYTOGENES AS A MODEL TO MEASURE THE 
CD8 T CELL IMMUNE RESPONSE TO INFECTION 
Listeria monocytogenes (Lm) is a gram positive, facultative intracellular bacteria most 
commonly associated with food-borne illness[39, 40]. It can be of most concern to those who are 
immunocompromised, pregnant women, and infants[9, 39, 40]. Lm has been used as a model 
pathogen as early as the 1960’s whenever researchers infected mice intravenously (IV) with Lm 
and noticed T cell mediated bacterial clearance (Fig. 2)[41]. A nice complement to studying Lm 
T cell dynamics is that there are numerous antigen specific epitopes available to track the clonal 
specific effector response and memory cell formation in these systems[40, 42]. Additionally, like 
most T cell immune response models, Lm responding effector and memory CD8 T cells can be 
phenotypically characterized by up or down regulation of surface marker expression of CD44, 
CD62L, KLRG1, and CD127 (IL-7R), where CD44hiCD62LloKLRG1hiCD127lo cells are deemed 
effector CD8 T cells and CD44hiCD62LhiKLRG1loCD127hi cells are deemed (central) memory 
CD8 T cells [20, 43-48].  
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1.2.3 TRACKING CLONAL-SPECIFIC CD8 T CELLS TO MEASURE THE CD8 T 
CELL IMMUNE RESPONSE 
The use of transgenic, clonal specific T cells to track an immune response has been well 
documented[40, 49-52]. Briefly, transgenic T cell receptor (TCR) inserts that recognize a 
specific MHC peptide are inserted into the mouse genome. One prominent example of this is a 
mouse model with TCR engineering to recognize ovalbumin residues 257-264 in the context of 
H2Kb (MHC I). Roughly 20% of all T lymphocytes will recognize this specific OVA residue. 
These mice can then be used to track recombinant OVA peptide specific pathogens over the 
course of listeria infection[40, 53, 54] when Lm has OVA antigen attached and are deemed Vα2 
Vβ5 OT-I transgenic mice [55-57]. 
 It is also important to note that the OT-I model can be used for mixed bone marrow 
chimera generation and adoptive transfer studies, where cells from up to three different animals 
can be distinguished in the host mouse. This is made possible due to genetic manipulation of the 
leukocyte common antigen CD45. WT (wildtype) B6 (C57BL/6J) mice commonly have the 
CD45.2 allele. However, allelic variants exist as seen in the “pep boy” (pepcb/BoyJ) CD45.1 
mouse or heterozygous CD45.1.2 mice[58, 59]. All variants are functionally identical and enable 
an easy way to track competitively adoptive transferred donor CD45.2 and CD45.1.2 cells into a 
CD45.1 congenically labeled recipient mouse. All leukocytes from a given donor will express 
their allelic CD45 counterpart which makes this model ideal for transplantation studies, 
including the above-mentioned adoptive transfer approach. Use of this system has been well 
documented [58, 60-62]. Further discussion of adoptive transfers can be found in the materials 
and methods as well as diagramed in Appendix D. 
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1.3 CD8 T CELL METABOLISM AND METABOLIC REPROGRAMMING 
1.3.1 INTRODUCTION TO EUKARYOTIC CELLULAR METABOLISM 
All living organisms require carbohydrates, lipids, and proteins for fuel. Carbohydrates 
are broken down into glucose prior to entering glycolysis, the process outside the mitochondria 
where one molecule of glucose is broken down into two molecules of pyruvate and a net yield of 
2 ATP molecules[63, 64]. Pyruvate will then go into the mitochondria where it will enter the 
tricarboxylic acid (TCA) cycle and be converted into acetyl-CoA. The majority of this acetyl-
CoA will become further fuel for cellular respiration, however some will also exit and go on to 
be banked as sterols and fatty acids, ketone bodies, or for protein acetylation. Importantly, the 
TCA cycle is also where fatty acids and amino acids join the central metabolism pathway[65, 
66]. Here, a series of oxidation reactions yields NADH, FADH, and GTP that go on to further 
fuel subsequent steps of cellular respiration to produce even more ATP. These metabolites enter 
the electron transport chain (ETC) where they undergo a series of reductions, where electrons are 
“transported” across various protein complexes with O2 being the final acceptor (oxidative 
phosphorylation)[67]. During this process, a proton gradient of released H+ is formed which 
eventually leads to the phosphorylation of ADP to ATP, establishing a net gain of 32 ATP 
molecules[68]. 
Where do proteins and lipids enter these processes? Most general biology textbooks do 
not discuss where macromolecules besides glucose enter the metabolic pathway. As mentioned 
above, the site of convergence is at the TCA cycle. Proteins undergo proteolysis and are broken 
down into amino acids prior to deamination and oxidation to acetyl Co-A[68]. A cartoon 
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combination of all of these processes with emphasis on β-oxidation can be visualized in Figure 3. 
For the purposes of this dissertation, lipid metabolism well be analyzed in greater detail below. 
 
 
Figure 3. Overview of cellular metabolism with focus on β-oxidation 
Eukaryotic cells use metabolites from sugars, proteins, and fats for energy. Sugars (glucose) typically undergo 
glycolysis prior to entering the TCA cycle and electron transport chain/oxidative phosphorylation in the inner 
mitochondria. Amino acids (proteins) undergo deamination prior to entering the TCA cycle as various intermediates. 
Fats (LCFAs) are broken down via b-oxidation, where some will enter the TCA cycle as acetyl-CoA while others 
will be used for fat storage, ketone body formation, and protein/histone acetylation. An in-depth lipid analysis 
follows bellow. 
 
1.3.2 A CLOSER LOOK AT LIPID METABOLISM 
Dietary fats are degraded intro triacylglycerols (TAGs) in the intestine. They are then 
taken up by the intestinal mucosa where they join cholesterol and apolipropoteins and are 
incorporated into chylomicrons.  Chylomicrons migrate through the bloodstream where they are 
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broken down into fatty acids and glycerol and enter extra hepatic target cells via various fatty 
acid transporters. Here, they can either be oxidized as fuel or re-esterified for storage. Free fatty 
acids will be specifically broken down by a process known as β-oxidation[68-70].  Prior to this, 
LCFA must cross the mitochondrial membrane, however, they are not able to do so without 
using the carnitine shuttle. The most critical and rate-limiting step in this shuttle process relies on 
the enzyme carnitine palmitoyltransferase 1 (CPT1), with the isoform of most interest to this 
dissertation being CPT1α[71, 72]. This enzyme enables LCFAs to cross the inner mitochondrial 
membrane by catalyzing the transfer of the acyl group of a long chain fatty acetyl-CoA from 
coenzyme A to l-carnitine, a product capable of mitochondrial membrane transport. Once in the 
mitochondria, a series of enzymatic processes is initiated by the oxidative removal of successive 
2-carbon units in the form of acetyl-CoA. In the case of 16 carbon palmitic acid, this means in 8 
cycles there will be a net of 8 two-carbon acetyl groups of acetyl-CoA. After the removal of 4 
hydrogen atoms, this will mean a net gain of 8 acetyl-CoA molecules that can enter the TCA 
cycle or fat storage. The delicate balance between fatty acid oxidation (FAO) and fatty acid 
synthesis (FAS) is regulated by the PPAR transcription factor family. 
FAS is regulated by a family of proteins known as sterol regulatory element-binding 
proteins (SREBPs)[73-76]. These proteins control de novo FAS using a canonical insulin-AKT-
mTOR-SREBP pathway that involves trafficking between the rough endoplasmic reticulum 
(ER), golgi, and nucleus[77]. SREBPs come in 3 flavors: SREBP1a is necessary for global lipid 
synthesis and growth, SREBP1c is involved in FAS and energy storage, and SREBP2 regulates 
cholesterol production[77]. 
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1.3.3 INTRODUCTION TO CD8 T CELL METBOLISM 
Given that CD8 T cells undergo such drastic phenotypic changes upon antigen encounter, 
it is not surprising that this is accompanied by changes in metabolism. Naïve CD8 T cells are in a 
relatively quiescent state and predominately use oxidative phosphorylation (OXPHOS) as their 
metabolic means[78-80]. However, when activated CD8 T cells undergo clonal expansion, they 
require a much higher energy yield in order to grow, proliferate, and maintain effector cytokine 
production[64, 78-82]. Activated T cells use an unconventional approach to accomplish this. 
Similar to cancer cells, activated T cells will rely primarily on aerobic glycolysis, or the Warburg 
Effect, in order to meet their increased energy demands. This means that even in the presence of 
oxygen, activated CD8 T cells prefer to quickly use aerobic glycolysis rather than the more 
energetically productive OXPHOS[83]. The most likely explanation for this phenomenon is that 
aerobic glycolysis enables proliferating cells to free up energy for important metabolites that  
growing cells need to produce more biomass[82-84].  Only a small portion of these effector CD8 
T cells differentiate into memory CD8 T cells that will again metabolically reprogram to use 
both OXPHOS and perhaps lipolysis to fulfill energy requirements [38, 85, 86]. A general 
overview of this can be found in Figure 4.  
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Figure 4. CD8 T cell metabolic switching 
As they switch from phenotypic states, CD8 T cells also perform metabolic switching. Naïve T cells are low energy 
and rely primarily on cellular respiration via the TCA cycle and oxidative phosphorylation (OXPHOS). Upon 
activation, T cells switch to primarily using aerobic glycolysis. Memory cells again switch to OXPHOS but, there 
are also reports that they may utilize lipid metabolism (beta oxidation), as indicated by red question marks. 
 
 
Is there a possible link between CD8 T cell metabolism and memory CD8 T cell fate? 
Numerous reports suggest differential gene transcription and surface marker signaling are critical 
for memory CD8 T cell survival[33, 37, 43, 87] but there is also a strong belief in the field that 
the metabolic switching from glycolysis to OXPHOS and FAO is another important 
determinant[79, 88, 89]. Reports show that T cells use FA signaling as key cell fate 
determinants, including whether or not for effector cells to differentiate into memory cells [90]. 
When FAS is inhibited early  in T cell priming to chronic viral infection, it was shown to limit 
memory precursor effector cell (MPEC) frequency[91], suggesting an important role for LCFAs 
?? 
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early in T cell activation and differentiation. It was previously discovered that when chemical 
inhibitors of glycolysis are administered during the effector phase that there is an enhancement 
of memory cell formation[92]. This is supported by seminal studies, performed by Pearce et al., 
that show that memory CD8 T cells prefer to use FAO metabolism. Early reports illustrated this 
by inhibiting TRAF6, an adaptor protein in the TNF-receptor, in all T cells of infected mice and 
saw an enhanced effector response but very poor memory CD8 T cell formation that was found 
to be a result of decreased transcription of genes related to FAO[38]. The group went on the 
show that when etomoxir is used to inhibit the rate limiting enzyme of FAO (CPT1α), that 
memory CD8 T cell formation is also inhibited[93].  
Recent reports have sparked controversy by suggesting that the effects of etomoxir were 
off target and a result of oxidative stress in the system[94, 95]. These studies suggest that much 
lower levels of etomoxir are all that are necessary to inhibit CPT1α and FAO and that when the 
physiological relevant level of inhibitor is used, that there is no effect on memory CD8 T cell 
formation[96] or macrophage polarization, another function thought to be determined by 
FAO[97]. In light of these recent studies, it is suggested that memory CD8 T cells do not rely 
directly on FAO, but rather DAG storage during the effector response in combination with de 
novo lipid synthesis. 
Lipid metabolism in T cells is a critical topic in the field of immunometabolism. How 
effector and memory T cells acquire external metabolites such as glucose[98, 99], glycerol[52], 
and neutral amino acids[100] has already been investigated. Even with the recent contradictory 
reports listed above, there is still evidence suggesting that CD8 T cells are importing exogenous 
lipids, as found when looking at another important group of memory CD8 T cells -- tissue 
resident memory (TRM) CD8 T cells[101] – and their preferential use of lipid transporters FABP4 
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and FABP5, critical for their formation [36]. Besides this information, very little is understood 
overall about how CD8 T cells use fatty acids and how, if at all, they use the import of 
exogenous free fatty acids (FFAs) during effector and memory responses. This knowledge gap 
represents an area of CD8 T cell immunometabolism worthy of further pursuit. 
1.4 INTRODUCTION TO LYSOPHOSPHOTIDYLCHOLINE 
Lysophosphotidylcholine (LPC) is a product of lysophospholipid (LPL) metabolism that 
can be generated from its precursors phospotidylcholine (PC) by the enzyme phospholipase A1/2 
[102-104]. It is either directly formed in the liver or by altering low-density lipoprotein (LDL) 
cholesterol in vitro. LPC consists of one hydrophobic fatty acyl chain and one hydrophilic polar 
choline group attached to a glycerol backbone. LPCs are present in roughly 3% of phospholipid 
membranes and make up roughly 8-12% of blood plasma[105]. In addition to this, many LCFAs 
are found in the cell plasma in their esterified form with LPC, the most common of these being 
LPC-palmitate and LPC-oleate[106]. LPC-docosahexanoic (LPC-DHA) also exists at lower 
levels. LPC species are critical for maintaining cellular homeostasis as well as added benefits 
such as wound healing and potential therapeutic treatments for both autoimmunity and 
neurodegenerative conditions [107]. There are hints that LPC may be important to the immune 
system – others have found a role for LPC as a negative regulator of innate and adaptive immune 
cell proliferation, under G2A signaling motifs[108] and that LPC is a significant component to 
viral transmission in Chagas disease through LDLs in infected insect saliva left at the point of 
infection on the skin[109]. The general form of LPC is shown in Figure 5 and is considered to be 
C24H50NO7P with the addition of various R group esterified LCFAs. 
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Once transported into the target cell’s cytoplasm, LPCs are processed into multiple 
products such as PC, phosphatidic acid (PA), diacylglycerol (DAG) and triglycerides (TAGs) to 
be used metabolically by the cell[102]. Since LPC acts as the chemical transporter of many 
species of LCFAs between cells, it is considered an important component to cellular metabolism. 
It is appreciated that DHA is the preferred dietary fatty acid for brain and eye development, 
particularly in infants as well as known other positive anti-inflammatory qualities of 
supplementation[110-113], however, until recently, it was not known how DHA was able to 
cross the blood brain barrier (BBB) and blood retinal barrier (BRB) and be delivered into the 
brain[114]. It was discovered in 2014 that Major Facilitator Superfamily Domain Containing 2a 
(MFSD2A) is the lipid transporter responsible for transporting LPCs across the BBB, BRB, and 
blood placental barrier[106, 115-117].  
 
 
 
Figure 5. Chemical structure of LPC 
The chemical structure of LPC where R is the variable fatty acid chain. 
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1.4.1 LPC IN T CELLS 
Very little is known about LPCs and T cells, including how and if CD8 T cells may be 
importing and using LPC species. Preliminary studies show a role for LPC as a chemoattractant 
for T cells, suggesting it may be important for T cell recruitment to atherosclerotic plaques[118]. 
There is also evidence that LPCs produce reactive oxygen species (ROS) and have (possible 
activation) signaling properties in Jurkat cells, an in vitro model for human CD8 T cells[119, 
120]. In CD4+ FOXP3+ CD25+ T regulatory (Treg) cells, LPC was found to increase their 
suppressive abilities through altering TGFβ signaling, a hallmark of Treg cells[121]. 
A unique subset of T cells, deemed invariant natural killer T cell’s (iNKT) known to have 
a invariant T cell receptor restricted to responding to glycolipids presented by the CD1d 
molecule[122, 123] show that they can be activated by CD1d-LPC complexes[124, 125]. This 
dissertation will not discuss iNKT-LPC interactions but will acknowledge my own preliminary 
data showing a potential relevancy of iNKT cells and LPC. 
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1.5 INTRODUCTION TO MFSD2A 
MFSD2A is a member of the major facility superfamily (MFS) protein transporter family 
which consists of 74 diverse subfamilies and nearly 25% of all membrane transporters in 
prokaryotes[126]. MFSD2A is a 12 domain transmembrane protein. It was previously believed to 
be an orphan transporter but now has a well-established role as a lipid transporter that bears a 
close resemblance to the bacterial Na+/melibiose supporter [106, 116, 127]. Spanning 14 exons 
and 7.7 kb, it is conserved through vertebrate evolution and has a wide tissue distribution in 
mouse with highest expression levels in kidney with cellular localization at the rough 
endoplasmic reticulum (ER) [116, 128, 129]. MFSD2A acts in a sodium-dependent manner to 
transport LPC species by a unique mechanism where LPCs are “flipped” by turning about 
Lys436 which carries the LPC from the outer to the inner cell plasma membrane[130]. The 
complete mechanism of active MFSD2A-LPC species transport is currently unknown, however 
recent studies have determined three critical steps to transport function: The LPC headgroup 
binding site, a hydrophobic cleft occupied by the fatty acyl tail of LPC, and a combination of 
three sets of ionic locks[130]. 
MFSD2A was first discovered as a fasting-induced gene that regulated PPARα and 
glucagon in the liver and brown adipose tissue (BAT), suggesting its role in lipid metabolism, 
growth, and thermogenesis [127, 128]. MFSD2A was subsequently found to be an important 
sodium-dependent tucinamycin antibiotics transporter in humans and when knocked out in 
human cell lines, tunicamycin uptake was significantly decreased [129]. This experiment 
supports MFSD2A’s importance at the ER and its role in the cellular stress response as well as 
the potential for transport roles for MFSD2A[131]. MFSD2A has also been found to be 
protective against intracerebral hemorrhage by inhibiting vesicular transcytosis post-
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hemorrhage[132]. More recently, MFSD2A has been implicated in BBB development and its 
important role as lipid transporter of DHA in the form of LPC across the blood brain barrier 
(BBB) [106, 133, 134]. DHA has been well documented for its critical role in brain development 
[110, 114, 135]. It is essential for normal brain growth and cognition. However, since the brain 
cannot synthesis DHA de novo, the mechanism of how it crossed the BBB was unknown until 
recently. In 2014, MFSD2A was found to be the major transporter of DHA across the BBB into 
brain endothelium, and it does so by transporting LPC-DHA in the form of LPC in a sodium-
dependent manner [106]. A cartoon illustrating how MFSD2A imports LPC-DHA across the 
endothelia of the BBB is illustrated in Figure 6. Using conditional KO models, it was shown that 
the brain tries to compensate for loss of exogenous lipid import by using FAS to synthesize its 
own, suggesting that MFSD2A is a negative regulator of SREBP1 and SREBP2[74].  
In the years since this seminal finding, MFSD2A has been found responsible for 
transporting DHA across the BRB [115] and placental barrier[117, 136, 137], noting, however, 
that  maternal DHA supplementation in pigs does not increase fetal brain accretion[136]. 
MFSD2A is also an important marker of central nervous system injury, as it was found to be a 
biomarker for spinal cord injury where the amount of endothelial cell damage correlated with the 
amount of MFSD2A loss in mice[138]. Interestingly, this study was the first to show a link 
between epigenetics and MFSD2A, showing that when miR-155 is expressed at lower levels 
after spinal cord injury and when this is combined with increased levels of MFSD2A, there is a 
reduced rate of paralysis.  
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Figure 6. MFSD2A and LPC-DHA interaction at the BBB 
MFSD2A actively transports LPC-DHA across the BBB in a sodium-dependent manner. It acts as a transmembrane 
pore enabling exogenous LPC-DHA to cross the endothelium of the BBB into the brain. Once there, LPC-DHA 
dissociates into DHA and phosphatidylcholine (PC). The complete mechanism of MFSD2A is currently unknown. 
 
 
Could there be potential therapeutic benefits to using MFSD2A as a transporter that 
carries LPC species across the BBB? One suggestion is that MFSD2A could be used as a target 
for drug delivery, potentially by coupling drug delivery with LPC[139]. MFSD2A co-localizes 
with GLUT1 in the brain, the transporter for exogenous glucose[106]. Studies have shown in 
mice that when dietary fish oil is supplemented in the diet, there is an increase in MFSD2A and 
GLUT1 levels in the BBB, which could increase overall brain health and decrease the risk of 
disease[140]. Contradictory to this, others have shown that fish oil makes its way across the BBB 
(and liver) independent of MFSD2A[141], so further research into using MFSD2A as an area of 
therapeutic benefit must be performed. 
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Although rare, there are a few families with autosomal recessive MFSD2A mutations on 
chromosome 1p within their pedigree[116, 142, 143]. The main phenotype is microcephaly, 
developmental delay, and intellectual disability, all of which may be not surprising given 
MFSD2A’s known importance in the brain. All families show point (missense) mutations 
responsible for protein changes although the exact point mutations vary by family. These data 
were able to create a link between loss of MFSD2A and brain disease due to lack of LPC-DHA. 
Immunophenotyping was not performed on the above individuals, so no known link between 
MFSD2A mutated individuals and CD8 T cells in humans is currently known. 
 
1.4.1 MFSD2A AND A LINK TO THE IMMUNE SYSTEM 
Immunological phenotypes due to alterations in MFSD2A have been reported. The 
earliest reports link back to MFSD2A and its importance in brain health. These include a role for 
MFSD2A and brain cancer metastasis prevention, showing a striking correlation between the 
ability of brain cancer to metastasize out of the brain with loss of MFSD2A. When the BBB 
loses MFSD2A expression and upstream TGFβ and bFGF signaling, tumors are no longer 
inhibited from progressing across the BBB[144]. The authors also note that these brain 
metastases show decreased lipid metabolism and decreased amount of DHA import. These data 
taken together suggests there may be a novel role for MFSD2A and DHA supplementation in 
preventing brain tumors from spreading. A role for MFSD2A mutations in gastric cancers has 
also been reported[145]. 
MFSD2A may be an important candidate gene for ulcerative colitis (UC). Patients with 
active UC were found to have decreased amounts of both DHA and MFSD2A, suggesting a role 
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for MFSD2A transport of DHA across the gut endothelium and that, when lost, causes increased 
inflammation. Rescue experiments were  successfully performed in mice where overexpression 
of MFSD2A caused a reversal of intestinal inflammation of UC[146]. This is the first study to 
show that MFSD2A is critical for resolving inflammation in UC and to suggest that lack of 
MFSD2A expression may indicate a possible autoimmune phenotype as UC is thought to be at 
least partially caused by autoimmunity[147]. 
Finally, MFSD2A+ cells are a contributing player to tissue regeneration. It was 
discovered that hepatocytes that express MFSD2A are capable of expansion following partial 
hepatectomy or chronic injury while those that are MFSD2A- are not capable of regrowth[148]. 
Furthermore, MFSD2A was determined to be a marker of liver zones and was the marker that 
distinguished final zonation following liver repopulation. These data show that MFSD2A is an 
important marker for tissue regeneration and that it may be possible to take these data to the field 
of tissue transplantation, specifically to promote cell turnover and fend off necrosis. 
1.6 LPC, MFSD2A, AND CD8 T CELLS 
I previously showed that MFSD2A and LPC were both increased following innate iNKT  
(not shown) and adaptive T cell activation[149]. I accomplished and generated these data by 
using a combination of molecular approaches including RNA, protein, and flow cytometry that 
nicely show that both MFSD2A and LPC increased in vitro and in vivo (Fig. 7 and Fig. 8) 
following CD8 T cell activation. These data in particular showed that MFSD2A and LPC are 
important very early in T cell activation, as mRNA expression is highest as early as 6 hours post 
in vitro activation and returns down to basal by day 5 post in vivo activation. Importantly, 
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MFSD2A expression levels are activation dependent, as shown by flow cytometry analysis 
where the CD44hi (a marker for T cell activation) cells are also the ones co-expressing increased 
levels of MFSD2A (Fig. 7C). Taken together, these preliminary experiments gave the basis of 
this dissertation project.  
 
Figure 7. MFSD2A characterization in WT CD8 T cells 
MFSD2A mRNA expression levels from CD8 T cells activated until given time point. B. MFSD2A protein levels 
out to given time point with beta-actin loading control. C. FACS plot of activated versus naïve CD8 T cells 
measuring MFSD2A relative to CD44. D. Activated or naïve OT-I CD8 T cells from adoptively transferred mice at 
given time point measuring MFSD2A intensity. All data except D. from in vitro activated CD8 T cells stimulated 
with α-CD3 and α-CD28. Data are representative of at least 3 independent experiments with 3 animals per group 
with p-values calculated using Student’s t test. 
 
 
I wanted to pursue studies designed to determine what would happen to activated effector 
CD8 T cells during acute infection with loss of MFSD2A. Would they still be capable of 
producing an effector response? Memory CD8 T may use FAO, or at least will use lipid 
metabolism for metabolic fuel to bank biosynthetic precursors for rapid proliferation during 
secondary antigen encounter. With loss of exogenous lipid import, would memory CD8 T cells 
form, function phenotypically, be maintained, and be capable of producing an efficient recall 
response to infection? These were all questions previously left unanswered until now.   
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Figure 8. TopFluor LPC levels increase with CD8 T cell activation 
CD8 T cells were activated in vitro with α-CD3 and α-CD28 for 48 hours. The last 4 hours of incubation, cells were 
co-cultured with 0.1uM TopFluor LPC prior to being ran on the cytometer. Data are representative of at least 3 
independent experiments with 3 animals per group with p-values calculated using student’s t test. 
 
1.7 MFSD2A AND PUBLIC HEALTH 
T cell metabolomics and metabolic reprogramming are currently an exciting field in 
immunology because of how cell metabolism can be used as a regulator for various cell 
processes including cell fate, epigenetic control, tumor regulation, inflammation control, and 
infection prevention and vaccine development[93, 150-155]. The mechanism by which effector 
T cells take up LCFAs and how it is regulated is still unknown. This represents a knowledge gap 
in the understanding of how T cells use exogenous lipids and if these LCFAs play a pivotal role 
in effector function and memory cell formation. The potential breakthrough of MFSD2A as the 
carrier molecule of LCFAs into activated T cells by means of chemical form LPC would fill a 
gap in the current understanding of T cell lipid metabolism by showing where and how CD8 T 
cells are using exogenous LPCs. Activated T cells require higher energy demands to properly 
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initiate an immune response, to clear infection, or tumors. Elucidating this pathway is very 
important to public health, as these metabolic instruments hold potential therapeutic benefits to 
patients and could provide future cutting-edge immunotherapies. In addition to this, The World 
Health Organization (WHO) and American Heart Association both recognize DHA as an 
important component to a healthy lifestyle[156, 157]. The research herein signifies an urgent 
need to understand and target how phospholipids, LCFAs, and DHA are imported into CD8 T 
cells and how they impact the immune response to infections, including recurrent infections that 
depend on a pool of nutrients for memory T cell functionality 
1.8 OBJECTIVES, AIMS, AND OVERALL HYPOTHESIS 
The main objective of this project was to expand current knowledge on MFSD2A in CD8 
T cells. A role for MFSD2A in any one immune cell type has still not been published. I was the 
first to show a potential role for MFSD2A in CD8 T cell activation during my master’s thesis. 
This current project looked more closely at what are the cellular consequences of loss of 
MFSD2A and LPC import into CD8 T cells.  Until recently, it was accepted that memory CD8 T 
cells prefer to use FAO and that central memory CD8 T (Tcm) cells in particular tend to use more 
exogenous lipid import rather then de novo synthesis. Newer findings suggested that FAO is not 
critical for memory CD8 T cell formation directly, but it is still within reason to assume that lipid 
metabolites are critical for biosynthetic precursor generation and regulation of FAS. Without 
MFSD2A and exogenous LPC import, I proposed there will be a catastrophic failure within CD8 
T cells early post-activation due to relatively high MFSD2A expression early on in the effector 
response, but also that MFSD2A was important for memory CD8 T cell formation and 
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maintenance well after initial antigen encounter. This hypothesis was further tested by being 
broken down into two broad specific aims, with multiple sub aims to be discussed for each: 
1.7.1 SPECIFIC AIM 1 
Specific Aim 1 explored a role for MFSD2A in the activation and differentiation of effector and 
memory CD8 T cells. This is the more phenotypically descriptive of the two aims of this project. 
This aim looked to answer the questions of what happens to CD8 T cells over the course of an 
infection without MFSD2A. This was tested primarily by using an adoptive transfer and listeria-
OVA model to investigate effector and memory CD8 T cells with conditional MSFD2A deletion.  
1.7.1.1 SPECIFIC AIM 1.1 
Specific Aim 1.1 investigated if MFSD2A is required for the effector CD8 T cell 
response to infection. Before diving in, MFSD2A-/- mice were tested to confirm there was no 
developmental defect in all T cell subsets. Then, mice were sacrificed at an early infection time 
point (d4) to measure bacteria clearance, with the idea being that MFSD2A-/- mice may have a 
delayed clearance since MFSD2A is expressed early. Next, mice were sacrificed at peak 
expansion and early contraction phases to examine phenotypic CD8 T cell activation marker 
surface expression as well as inflammatory cytokine production. Since MFSD2A does seem to 
be elevated early on in T cell activation, I hypothesized that there will be an effect on cytokine 
production during these early time points. 
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1.7.1.2 SPECIFIC AIM 1.2 
 Specific Aim 1.2 investigated if MFSD2A was required for memory CD8 T cell 
maintenance. In this aim, mice were taken out to d40 post-infection (pi). Cell frequency and 
phenotype were both analyzed similarly to Aim 1.1. I anticipated that by the time MFSD2A-/- 
mice reached memory, that I would see critical defects in their memory CD8 T cells, whether it 
be the relative amount of cells turning over to memory cells or as seen by having decreased 
fitness relative to MFSD2A+/+ mice. I hypothesized that a significantly reduced import of 
exogenous LPC would alter normal CD8 T cell metabolism and would be responsible for any 
phenotype seen here. Biochemical LPC levels were further investigated in Aim 2. 
1.7.1.3 SPECIFIC AIM 1.3 
 Specific Aim 1.3 asked if MFSD2A is required for a successful CD8 T cell recall 
response to recurrent listeria infection. Since I hypothesized that MFSD2A will be critical for 
memory CD8 T cell formation, I rationalized that without memory CD8 T cells, I would see a 
futile to none recall response upon secondary infection with listeria. I planned to measure 
cytokine production in whatever memory cells were available at this time and assessed 
functionality of recalled memory cells that lack MFSD2A. 
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1.7.2 SPECIFIC AIM 2 
 The overall goal of Specific Aim 2 was to determine the metabolic and genetic 
requirements for exogenous LPCs during CD8 T cell activation and memory cell maintenance.  
Aim 2 explored what consequences cells were faced with when MFSD2A was lost. It was the 
more mechanistic of the two aims. Aim 2 was accomplished by using a multi-disciplinary 
approach, including lipidomics, proteomics, metabolic flux assays, and genetic approaches. 
There was evidence that exogenous lipids are important for FAO and also contradictory reports 
that they were not. Due to these recent reports, I hypothesized that loss of MFSD2A may not 
directly affect FAO processes directly linked to memory cell metabolism and formation, but 
rather that decreased LPC import early on may result in memory CD8 T cells not banking 
enough nutrients to sustain their longevity and that this may be held responsible for some of the 
downstream phenotypes that were seen. Three sub aims were used to answer the questions in 
Aim 2. 
1.7.2.1 SPECIFIC AIM 2.1 
Specific Aim 2.1 looked to see if there was decreased exogenous LPC import with loss of 
MFSD2A. Since MFSD2A was a known transporter for LPC species, I hypothesized that there 
was a significant decrease in the amount of LPC being imported into CD8 T cells. I investigated 
LPC import multiple ways, including flow cytometry, thin layer chromatography (TLC), 
confocal live-cell imaging, and lipidomic mass spec approaches. 
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1.7.2.2 SPECIFIC AIM 2.2 
The goal of Specific Aim 2.2 was to determine what were the metabolic outcomes of 
uptake of LPC through MFSD2A by effector and memory CD8 T cells. This was performed 
using a Seahorse Metabolic Flux analyzer to profile both the oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR). I anticipated MFSD2A-/- mice would show altered 
cellular metabolism both at the effector and memory stages. These data showed how loss of LPC 
import by LPC altered the overall cellular metabolism and how this may be responsible for 
differences in effector and memory CD8 T cells in the absence of MFSD2A. Since different CD8 
T cell subsets have different metabolic profiles, it was possible that with loss of MFSD2A (i.e., 
being somewhat metabolically deficient) the OCR and ECAR profiles in MFSD2A-/- may differ 
from what was expected in an MFSD2A+/+ mouse. 
1.7.2.3 SPECIFIC AIM 2.3 
Specific Aim 2.3 investigated the genetic consequences of loss of MFSD2A. Here, I was 
looking to prove the role of MFSD2A and LPC in genetic regulation in effector and memory 
CD8 T cells. I wanted to discover what, if any, genes may be expressed differentially with loss of 
MFSD2A. This included phenotypic CD8 T cell genes as well as genes related to the cell’s 
metabolome including metabolic enzymes, substrates, and pathways. I tried to answer these 
questions using a mixture of approaches, including qPCR and RNA-sequencing. Overall, I 
hypothesized that there were differentially expressed genes in the absence of MFSD2A and that 
these altered transcripts helped to explain why loss of MFSD2A was detrimental to cell health. 
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 The overall hypothesis of this project was summarized in the figure below (Fig. 9). I 
anticipated based on work by others at the BBB and my own preliminary data that MFSD2A and 
LPC played a similar role in effector and memory CD8 T cells to what occured in the BBB. 
After T cell activation, MFSD2A was most highly expressed. I expected MFSD2A to play a role 
in normal effector function in CD8 T cells. Because memory CD8 T cells were reliant on a bank 
of metabolites that may be determined early on in the effector phase post-infection, I also 
expected that memory cell formation and maintenance would be lost with loss of MFSD2A. 
Overall, I hoped to prove via accomplishing the above Specific Aims that loss of MFSD2A was 
severely detrimental to both the effector and the memory CD8 T phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
 
 
 
 
    
 
 
Others have shown a role for MFSD2A and LPC at the BBB (left hand). MFSD2A enables LPC-DHA to cross the 
BBB endothelium into the brain, where LPC-DHA dissociates into PC and DHA. I hypothesize a similar role for 
MFSD2A in activated CD8 T cells where MFSD2A transports LPC species across the cell membrane to enter the 
cell’s metabolome. LPC species then play a role in CD8 T cell effector function and memory cell formation and 
maintenance.  
Effector function? 
Memory precursors? 
Figure 9. Proposed role of MFSD2A and LPC in activated CD8 T cells 
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2.0  MATERIALS AND METHODS 
2.1 MFSD2A CONDITIONAL KO MOUSE 
MFSD2A Flox mice were kindly donated by Dr. David Silver. Loxp sites were inserted 
above critical exon 3 on chromosome 4. Mice were “conditional ready” (floxed) upon arrival. 
CD4 cre mice were purchased from the Jackson Laboratory. These mice contain CD4 enhancer, 
promoter, and silencer sequences driving the expression of cre recombinase. When bred to 
conditional ready MFSD2A flox mice, cre-mediated recombination will result in deletion of 
MFSD2A on all T cells during the early double positive stage of thymic development, i.e., 
MFSD2A will be knocked out of all CD4 and CD8 T cells. 
Additionally, most in vivo work was performed using conditional MFSD2A knockout 
mouse that also has a transgenic Vα2 Vβ5 TCR, deemed OT-I mice. The purpose for such mice 
is listed in the background. Briefly, the use of this transgene serves as a competent model to 
track antigen-specific CD8 T cell response to infection. Wildtype OT-I mice were bred to 
MFSD2A conditional knockout mice and all lines were backcrossed to C57BL/6J stain for 
multiple generations, including a continuation of in-house backcrossing to eliminate any concern 
for rejection. CD4 cre only littermates were used as controls. MFSD2A-/- mice were phenotyped 
in the naïve state to show there were no developmental defects (Figs. 10 and 11). Genotyping 
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primers can be found below in Appendix B. A diagram of mouse models being used can be 
found in Appendix D. 
2.2 LYMPHOCYTE ISOLATION FROM TISSUE 
Mice were sacrificed at a given experimental time point according to the University of 
Pittsburgh’s IUCAC protocol. Spleens and thymi were extracted into cold PBS 2% FCS 
(hereafter referred to as FACS buffer), red cell lysed, and isolated into a single cell suspension 
prior to counting. Lymphocytes were counted using standard light microscopy/Trypan blue or by 
using Countess automated cell counter (Life Technologies). 
Peripheral blood lymphocytes (PBL) were collected from the submandibular vein via 
lancet (Goldenrod) into tubes containing 500 µL PBS with 0.5% EDTA. Blood was spun down 
prior to red cell lysis and staining for surface antigens. 
2.3 IN VITRO CD8 T CELL ACTIVATION 
Lymphocytes were isolated as shown above. CD8 T cells were enriched from total 
lymphocytes by using negative selection enrichment. Whole lymphocyte suspension was 
incubated with biotinalyated antibodies to CD4, CD11c, CD11b, B220, and NK1.1 (all 
eBioscience) and then incubated with streptavidin microbeads (Milteny) followed by negative 
selection via column prep (Milteny). CD8 T cells were then counted and plated at 2x106 
cells/well in complete T cell media (RPMI, 10% FBS, 2% of each l-glutamine and pen-strep, and 
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0.5% β-mercaptoethanol). Prior to plating, a 24 well plate was coated in anti-CD3 (eBioscience) 
for a minimum of 2 hours at 37C. Cells were cultured in wells coated with plate bound anti-CD3 
and co-cultured with soluble anti-CD28 (eBioscience) to a given time point.  Naïve controls were 
cultured with 1 ng/mL IL-7 to promote viability. 
For ex vivo OT-I CD8 T cells, whole lymphocyte suspension was plated with soluble 
OVA peptide. 500x protein transport inhibitor cocktail (eBioscience) was added the last 3 hours 
of a 6 hour peptide stim. 
2.4 ADOPTIVE TRANSFERS AND IN VIVO INFECTIONS 
1x104 transgenic CD45.1.2 MFSD2A+/+ OT-I and CD45.2 MFSD2A-/- OT-I CD8 T cells 
were adoptively transferred retrorbitally into congenically labeled CD45.1 C57BL/6J mice. The 
50:50 ratio was verified by flow cytometry prior to injection. Mice were sex matched per each 
experiment to remove any cell rejection due to the Y chromosome. The following day, mice 
were injected retrorbitally with 5000 CFU listeria-OVA. Listeria was grown in tryptic soy broth 
until reaching an OD600 between 0.11-0.09 which is considered to be late-log phase growth. Mice 
were bled from the submandibular vein at indicated time points into PBS 0.5% EDTA. Spleens 
were harvested at indicated time points for downstream analysis. Time points correlated to 
different CD8 T cell phenotypes as seen in Figure 1. A diagram of the overall model is in 
Appendix D.  
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2.5 MIXED BONE MARROW CHIMERA GENERATION 
CD45.1 mice recipient mice were irradiated with 1000 rads to destroy rapidly dividing 
(immune) cells one day prior to chimera transplantation. Mice received clean cages, fresh food, 
and bottled water containing antibiotics sulfamethoxadole and trimethoprim at 2 mg/mL every 2-
3 days for the first two weeks following irradiation. 
CD45.1.2 MFSD2A+/+ and CD45.2 MFSD2A-/-  sex matched donor mice were sacrificed 
the following day and hind limbs collected (femur, tibia, fibula). Muscle and connective tissue 
was cleaned from bones and bone marrow was isolated in RPMI 20% FCS using 28 gauge 
needles. Bone marrow was collected, red cell lysed, and counted prior to depletion of all B, T, 
and NK cells via biotinylated antibodies and streptavidin microbeads (eBioscience and Miltenyi). 
Bone marrow as recounted following depletion. Bone marrow was injected into irradiated 
CD45.1 recipient mice retroribitally in sterile PBS in a 50:50 ratio of 5x106 total cells/mouse. 
2.6 BACTERIAL CLEARANCE STUDIES 
Mice were directly infected with listeria and sacrificed d4 pi. Spleens and livers were 
harvested for whole tissue homogenate. Whole tissue was diluted 1:10 in sterile PBS and then 
pipetted onto pre-warmed tryptic soy agar plates in a volume of 200 µl in duplicate. Homogenate 
was spread evenly across plates using disposable cell spreaders (Fisher). Plates were incubated at 
37C 5% CO2 for 24-36 hours before colonies were counted. 
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2.7 FLOW CYTOMETRY AND CELL SORTING PROTOCOL 
For general flow cytometry, lymphocyte single cell suspensions were aliquoted to 96 well 
plates, stained with live/dead dye in PBS at RT, washed, then followed by Fc block (BioLegend). 
Cells were next stained for surface antigens at a 1:200 dilution in FACS buffer at 4C. For 
intracellular staining, cells were fixed and permeabilized using Cytofix/Cytoperm (BD 
Biosciences) per manufacturer’s instructions. Cells were stained for cytokines at 1:200 dilution 
in 1x Cytofix/Cytoperm buffer for 30 minutes at 37C prior to being ran on the cytometer. A list 
of all antibodies used for this project can be found in Appendix C. 
For cell sorting, similar protocols to general cell staining were followed, with the 
exception being that whole spleens were stained in 1 mL PBS or FACS buffer. 
2.8 ANNEXIN V AND BRDU STAINING 
Annexin V and caspase 3&7 staining was performed according to manufacturers’ 
protocols (BD Biosciences and Thermo Fisher Scientific). Annexin V samples were ran on the 
cytometer within a half hour of staining.  
Mice received BrdU (Millipore Sigma) injections IP at 2 mg/mL on the first day of 
treatment. They then received bottled BrdU H2O at 200mg/mL plus 1.5% sucralose for 2 weeks 
with fresh bottles being given every 2-3 days. Water bottles were protected from light. BrdU is 
considered a chemical hazard and proper labeling and disposal was given in accordance to 
University of Pittsburgh’s Environmental Health and Safety. Mice were given an additional IP 
injection of BrdU the evening prior to sacrifice. Mice were sacrificed the morning of treatment 
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d15, surface stained according to previously described flow cytometry protocols, and then 
stained for BrdU incorporation following the kit’s manufacturer’s protocol (BD Biosciences). 
2.9 REAL TIME PCR 
Cells were lysed and RNA was processed using RNeasy micro PLUS kit (Qiagen). cDNA 
was isolated using a traditional first-strand synthesis kit (Genecopeoia). qPCR was performed on 
an Applied Biosystems StepOne real-time PCR machine using either SYBR green assays or 
TaqMan probes. Primer sequences and probe ID can be found in Appendix B. 
2.10 WESTERN BLOTTING 
For MFSD2A and H3K27ac westerns, enriched or sorted cells were prepped under non-
denaturing and non-reducing conditions using RIPA buffer plus protease inhibitors (Roche) with 
head-over-tail rotation at 4C for 1 hour. Supernatant of MFSD2A micelles was collected 
following a 10 minute spin at 4C, max speed. Protein concentration of lysed samples was 
determined using BCA assay (Thermo) and then samples were ran on a 5-20% gradient gel (Bio-
Rad) and transferred onto PVDF membrane using a semi-dry Power Blotter (Thermo). Primary 
antibody for MFSD2A was purchased by Abcam and verified by a homemade antibody kindly 
donated by Dr. David Silver. Membranes were visualized on Protein Simple FlouroChem 
machine (Biotechne). Quantification studies were performed using ImageJ software (NIH). A list 
of all antibodies used can be found in Appendix C. 
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2.11 GLOBAL LIPIDOMICS 
Lipid extraction from blind in vitro activated or naïve MFSD2A+/+ and -/- CD8 T 
homogenates was done according to the Bligh and Dyer method. The organic phases were 
pooled together and dried in a speed vac. Samples were dissolved in 100 μL of CHCl3/MeOH 
1:1 (v/v) prior to MS analysis. Samples were injected into a liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) instrument (1290 Liquid Chromatography System, and 6460 QqQ, 
Agilent Technologies). Quality controls and blanks were injected after every 6 sample injections 
to monitor stability of the instrument response and carryover. Phospholipids were quantified at 
the sum composition level using multiple reaction monitoring (MRM) with precursor to 
headgroup transitions. Quantification data were extracted using MassHunter Quantitative 
Analysis (QQQ) software, and data were manually curated to ensure correct peak integration. T 
cell samples were generated and then shipped to the lab of Dr. David Silver at Duke-NUS, 
Singapore where lipidomic profiling was ran and analyzed by Bernice Wong, Juat Chin Foo, 
Amaury Cazenave-Gassiot, and Markus Wenk. 
2.12 CONFOCAL LIVE-CELL IMAGING 
CD8 T cells were activated in vitro and cultured with TF-LPC as described above. Prior 
to imaging, cells were stained with Hoechst at a 1:1000 dilution at 4C. Stain was rinsed 2x with 
PBS prior to microscopy. Samples were imaged using a Nikon A1 point scanning confocal with 
a 60x 1.40 N.A. objective and Tokai Hit environmental controller.  Complete volumes of cells 
were acquired at 1 um steps and volumes were reconstructed and analyzed using Nikon’s NIS 
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Elements software.  To define perinuclear space a threshold was established using the nuclear 
signal labeled with Hoechst fluorescent nuclear marker.  The nuclear threshold was then dilated 
and the original nuclear threshold was subtracted from the dilated mask leaving behind a donut 
shaped region corresponding to the immediate perinuclear space in the cell, under-which 
intensity measurements were performed. Microscopy experiments were performed in partnership 
with the University of Pittsburgh Center for Biologic Imaging (CBI) with Callen Wallace under 
the guidance of Dr. Simon Watkins. Callen Wallace and Eric Hzyny assisted with data analysis. 
2.13 SEAHORSE METABOLIC FLUX 
CD8 T cells were sorted at a given time point like previously described. Cells were taken 
over to Hillman Cancer Center where they were plated at a determined density into a 96 well 
plate. The Seahorse MitoStress test was performed on these samples. Seahorse experiments were 
performed in partnership with Ashley Menk in the lab of Dr. Greg Delgoffe. 
2.14 RNA SEQUENCING 
MFSD2A+/+ and -/- CD8 T cells were sorted from competitive adoptive transfer mice at 
d40 p.i. into RLT PLUS lysis buffer (QIAGEN). Samples were delivered to the Sequencing Core 
at Children’s Hospital of UPMC. RNA was isolated and quantified via ScreenTape (Agilent). 
Library prep was performed prior mid-output single-end read 75bp mRNA-sequencing with 40M 
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reads/sample. Data analysis was performed using CLC Genomics Workbench 11 (QIAGEN), 
Partek Genomics Suite (Partek, Inc.), and IPA pathway analysis (QIAGEN). 
2.15 HUMAN SAMPLE COLLECTION 
Human buffy coats were purchased de-identified from Central Blood Bank. Lymphocytes 
were isolated from PBL by using a Ficoll gradient (GE Healthcare) and then sorted for whole 
CD8 T cells or naïve, effector, and memory CD8 T cells prior to in vitro stimulation using 
human αCD3 and αCD28 (eBioscience). Cells were then used for downstream molecular 
applications. 
2.16 CHROMATIN ACCESSIBILITY ASSAY 
Chromatin accessibility was assayed by using the EpiQuikTM Chromatin Accessibility 
Assay Kit (Epigentek). MFSD2A+/+ and MFSD2A-/- effector CD8 T cells were sorted at d7 pi as 
described. Sorted cells were lysed prior to chromatin extraction. Chromatin was either digested 
or saved as an undigested control prior to DNA clean-up and downstream qPCR analysis using 
designed qPCR genomic primers for the IFNγ locus. Fold enrichment was calculated by taking 
the ratio of the Ct values between digested and undigested chromatin samples. 
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3.0  SPECIFIC AIM I RESULTS 
3.1 MFSD2A-/- MOUSE DEVELOPMENTAL PHENOTYPING 
MFSD2A conditional knockout mouse was generated as described above. To verify no 
developmental defects with loss of MFSD2A, I first phenotyped naïve T cells.  Naïve 
phenotyping studies were performed in thymic and peripheral tissue (spleen) in 8 week old mice 
and analyzed relative to littermate controls. Prior to phenotyping, CD8 enriched splenocytes 
were activated in vitro with anti-CD3 and anti-CD28 for 72 hrs and analyzed by qPCR to 
confirm conditional deletion of MFSD2A was successful (Figure 10A). These data were further 
supported by flow cytometry analysis, showing that there is reduced MFSD2A protein 
expression by FACS (Figure 10B). 
 
Figure 10. MFSD2A conditional knockout confirmation 
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Real-time PCR (A) and flow cytometry analysis (B) was performed on 72 hr in vitro activated CD8 T cells. CD8 T 
cells were activated using anti-CD3 and anti-CD28. Data are representative of 2 independent experiments with at 
least 3 mice per group. 
 
Next, naïve thymocytes were analyzed by flow cytometry. As mentioned above, 
MFSD2A was conditionally knocked out during the double positive (DP) stage of thymic 
development, so it was important to verify that cells were undergoing normal thymic 
development. Mice were analyzed for the ratio of CD4:CD8 positive cells (Figure 11A) as well 
as total thymocyte cell counts (Figure 11A quantification). No differences were detected in these 
data. To further confirm, DP and CD4 and CD8 single positive (SP) cells were also quantified to 
no significant differences (Figure 11B). Thymocytes were critically analyzed for surface markers 
related to thymocyte development through the double negative (DN), DP, and SP stages and no 
differences were found (data not shown). Overall, these finding support that there was no 
significant differences in T cell development due to loss of MFSD2A and that it was okay to 
move forward with this mouse model. 
 
 
Figure 11. MFSD2A loss does not alter thymic development 
Thymocytes were isolated into a single cell suspension and stained for phenotype distinguishing surface markers 
prior to being ran on a flow cytometer. A. CD4:CD8 staining and quantification of total cells found within the 
A B 
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thymus suspension. B. Further quantification of thymic subsets with and without MFSD2A. Data are representative 
of 3 independent experiments with at least 3 mice per group. 
 
 
T cell phenotyping was performed in the periphery to confirm that cells migrated out of 
the thymus to secondary lymphoid tissue as expected. No noticeable differences were detected in 
the number of CD4 or CD8 positive splenocytes (Figure 12A) however there was a significant 
difference in the number of total splenocytes. Spleens from MFSD2A-/- mice appeared larger, 
however they also appeared to have a normal range of the most common splenic cell subsets 
including T cells, B cells, NK cells, dendritic cells, and macrophages (data not shown). Why 
MFSD2A-/- mice had larger spleens with more total cells has yet to be determined and may be 
further explored in the future. Finally, since T activation studies were planned for future 
experiments, we wanted to confirm that MFSD2A-/- mice had comparable numbers of CD44hi 
cells in the naïve state relative to MFSD2A+/+ mice (Figure 12C). No significant differences were 
found between naïve mice. CCR7 levels were also within normal range, indicating no migratory 
problems with loss of MFSD2A (data not shown). 
I originally became interested in MFSD2A because it was found to be one of the most 
differentially expressed genes in a microarray of NKT cells performed previously by the lab. 
Because of these findings, I wanted to confirm that splenic NKT cell populations were found 
within the expected frequency following loss of MFSD2A. Indeed, no differences in NKT cell 
frequency were determined (Fig. 12B). I was able to conclude that conditional loss of MFSD2A 
did not affect T cell development in the thymus or migration into secondary lymphoid tissues. 
Although differences in total splenic cell counts were noted, these data were conclusive enough 
for us to justify moving on to further phenotype MFSD2A-/- CD8 T cells in the effector and 
memory states. 
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Figure 12. MFSD2A loss does not alter migration to peripheral lymphoid tissue 
Naïve spleens were harvested from MFSD2A-/- mice or littermate controls and stained using surface marker 
antibodies and/or tetramer prior to running samples on a flow cytometer. A. CD4:CD8 T cell frequencies in spleen 
and quantification of total splenic cells. B. Frequency of NKT cells. C. Measurement of CD44 and CD62L 
activation markers, backgated on CD8 T cells. Data are representative of 3 independent experiments with at least 3 
mice per group with statistical calculations made using student’s t-test. 
 
 
 
 
 
 
A B 
C 
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3.2 MFSD2A-/- EFFECTOR CD8 T CELL RESPONSE 
After confirming there were no developmental defects accompanied with loss of 
MFSD2A, I next tested how MFSD2A deficit CD8 T cells would respond to acute infection with 
Listeria-OVA. I accomplished this by directly infecting MFSD2A-/- and littermate control mice 
retro-orbitally with 5000 CFUs of Listeria-OVA. First, I determined if MFSD2A deficient mice 
were able to clear bacteria as quickly as wild type (WT) mice. Mice were sacrificed d4 pi and 
whole tissue homogenates were made of spleen and liver prior to plating on tryptic soy agar 
plates. Colonies formed as early as 24 hrs after incubation, however there was no significant 
differences in CFUs between MFSD2A+/+ and MFSD2A-/- mice in both liver and spleen (Figure 
13), which led to the conclusion that MFSD2A deficient mice were not impaired with bacterial 
clearance. In agreement with this, mice directly infected with Listeria-OVA appeared to not have 
any striking phenotypic differences in their immune responses either(Supplemental Figure 2), so 
it was decided to try a competitive model to examine of MFSD2A-/- CD8 T cells were less fit in a 
competitive environment.  
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Figure 13. No difference in bacterial clearance with loss of MFSD2A 
Quantification of colony forming units (CFU/mL) day 4 post-infection with Lm-OVA in spleen and liver, with and 
without MFSD2A. Data are representative of 2 independent experiments with at least 3 mice per group. Statistical 
significance calculated using Student’s t-test. 
 
For future experiments, I used a competitive adoptive transfer approach where recipient 
CD45.1 mice received both sex-matched MFSD2A+/+ CD45.1.2 and MFSD2A-/- CD45.2 donor 
OT-I CD8 T cells. Cells were transferred retro-orbitally at 1:1 ratio of 10,000 cells each (see 
Appendix D). Mice received 5000 CFUs of lm-OVA retro-orbitally the following day. Mice then 
undergo a typical acute CD8 T cell immune response following infection which can be tracked 
by examining the response via the donor OT-I CD8 T cells.  
Early post-infection (d5) until d10, there was a slight skewing from the original 1:1 ratio 
to a 3:2 ratio in favor of the knockout, however by d13 (early contraction) this trend has 
disappeared (Figure 14A and B). These data were statistically significant at d7 and d10 pi, 
however, it was hypothesized that these differences are physiologically irrelevant in relation to 
the overall infection response due to the downstream analysis, to be discussed. When the 
frequency of CD44hi CD62Lhi MPEC cells is examined, there was a trend in reduction of 
MFSD2A-/- cells as early as d7 pi (data not shown). This discrepancy continued out to d10 and 
suggested that MFSD2A was important in MPEC and central memory cell formation. These data 
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were supported by a decrease in the KLRG1lo CD127hi cells by d10, also suggestive of a defect 
in MPEC generation (Supplemental Figure 1). 
To measure effector function, I performed an ex vivo stimulation at d7 and d10 pi using 
OVA peptide. For these experiments, CD8 T cells were unenriched and stimulated with OVA 
peptide alone for an indicated amount of time. By d10 pi, MFSD2A-/- cells were producing less 
inflammatory cytokines IFNγ and TNFα (Fig. 14C), suggesting that loss of MFSD2A affects 
cytokine production as early as d10 post-infection.  
 
Figure 14. MFSD2A-/- primary effector response following infection 
Mice received equal amounts of MFSD2A+/+ and MFSD2A-/- OT-I CD8 T cells prior to infection with 5000 CFUs 
lm-OVA. A. Time course of effector response showing frequency of MFSD2A+/+ and MFSD2A-/- cells at indicated 
time point. B. Graphical representation of frequency of MFSD2A+/+ and MFSD2A-/- cells at indicated effector time 
point. C. Intracellular staining of inflammatory cytokine production at d10 pi following a 6 hour stim with OVAp 
with golgi stop the last 3 hours. A and B are from bleeds, C and D are splenic data. Data are representative of 3 
independent experiments with at least 3 mice per group with p-values calculated using student’s t test or using one 
way ANOVA adjusting for multiple comparisons. 
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Next, to confirm if the above findings were cell extrinsic or cell intrinsic, I generated 
mixed bone marrow chimeras and performed similar effector experiments to those performed 
using the competitive adoptive transfer approach. Mice showed a similar ratio of cells during the 
primary expansion phase, including OVA tetramer specific CD8 T cells (Figure 15A and B). 
However, when stimulated with OVAp, I saw that indeed those cells lacking MFSD2A were 
poorer at secreting inflammatory cytokines (Figure 15C). These data matched what was found in 
the mixed adoptive transfer system, suggesting that the MFSD2A-/- CD8 T cells were responsible 
for the effector phenotype seen here in a cell intrinsic manor. 
 
 
Figure 15. MFSD2A-/- mixed chimera primary effector response following infection 
Irradiated CD45.1 host mice received equal amounts of MFSD2A+/+ CD45.1.2 and MFSD2A-/-  CD45.2 mixed bone 
marrow cells and were left 8 weeks to recover. Mice were then infected with 5000 CFU lm-OVA. The primary 
expansion of CD8+ CD44hi cells and OVA-tetramer+ cells was measured at indicated effector and contraction time 
points (A and B). C. FACS plots and quantification of mice were sacrificed at given time and stimulated ex vivo 
with OVAp for 6 hrs followed by 3 hrs of golgi stop prior to intracellular IFNγ staining. A and B are from bleeds, C 
and D are splenic data. Data are representative of 3 independent experiments with at least 3 mice per group with p-
values calculated using student’s t test or using one way ANOVA adjusting for multiple comparisons. 
A 
 
B
 
C 
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 As a control to confirm that the phenotype was not due to OVA antigen alone, I infected 
a separate group of mixed-bone marrow chimera mice with listeria attached to GP33 antigen. 
Although a more difficult model to work with due to poor GP33 tetramer-specific FACs staining, 
cytokine production data as seen in Fig. 15C using listeria-OVA successfully repeated using 
listeria-GP33 antigen and gating on the CD44hi cells rather than the tetramer positive population 
(Fig. 16). 
 
 
Figure 16. MFSD2A-/- decrease in cytokine production is not restricted to OVA antigen 
Irradiated CD45.1 host mice received equal amounts of MFSD2A+/+ CD45.1.2 and MFSD2A-/- CD45.2 mixed bone 
marrow cells and were left 8 weeks to recover. Mice were then infected with 5000 CFU lm-GP33. FACS plots and 
quantification of splenocytes that were sacrificed at given time pi and stimulated ex vivo with GP33p for 6 hrs 
followed by 3 hrs of golgi stop prior to intracellular IFNγ staining. Data are representative of 1 independent 
experiment with at least 3 mice per group with p-values calculated using student’s t test. 
3.2.1 MFSD2A IN HUMAN EFFECTOR CD8 T CELLS 
Because MFSD2A is conserved through evolution and there are known families with 
MFSD2A mutations, I found it of interest to look at healthy human donor blood for MFSD2A+ 
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CD8 T cells. Buffy coats of human peripheral blood lymphocytes (PBL) were received de-
identified from Central Blood Bank and primary lymphocytes were isolated using a Ficoll 
gradient. Cells were sorted based on distinguishable surface marker expression for naïve and 
effector CD8 T cells. Sorted cells were processed for qPCR and Western Blot analysis. I found 
that MFSD2A expression was double in human effector CD8 cells compared to naïve (Figure 
17A) and that this is also true when looking about protein levels (Figure 17B). Although human 
studies were not developed for this project past this preliminary work, it may be worth pursuing 
in the future along with the other future directions that follow. 
 
 
Figure 17. MFSD2A levels in human PBL samples 
Human PBL was sorted for naïve and effector CD8 T cells and then analyzed for MFSD2A levels. A. Flow 
cytometry plot of human PBL sorting schematic and quantification of relative MFSD2A expression following real-
time PCR. B. Western Blot image for MFSD2A protein levels in human naïve and effector CD8 T cells with β-actin 
loading control. Data is representative of 2 unique experiments from 2 sorted human donors (A, left) where 1 donor 
was used for mRNA (A, right) and 2 were used for western blotting (B). 
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3.3 MFSD2A-/- MEMORY CD8 T CELL RESPONSE 
I wanted to determine if there was a role for MFSD2A in memory CD8 T cell formation. 
Due to the possibility that memory CD8 T cells use FAO and their reliance on metabolities from 
the primary response, I hypothesized that those CD8 T cell that were lacking MFSD2A would be 
critically impaired in generating a robust and functional memory pool compared to wild type. 
Competitive adoptive transfer mice were taken out to what is considered in the field to be an 
acceptable memory CD8 T cell time point, d40 pi. Indeed, by d40 pi, there was a highly 
significant reduction in the memory CD8 T cell pool compared to MFSD2A+/+ mice (Figure 
18A). These data also repeat when looking at mixed bone marrow chimera mice taken out to 
memory (Supplemental Figure 3). In addition to their decreased frequency, MFSD2A-/- mice 
showed an altered surface marker phenotype (Figure 18 B and C). Central memory CD8 T cells 
are typically CD44hiCD62LhiKLRG1loCD127hi. In the case of the MFSD2A-/- mice, their surface 
marker profile at memory more closely resembled effector memory CD8 T cells as they were 
CD44hiCD62LloKLRG1hiCD127lo. This effector-like phenotype was not in agreement with the 
above effector time point data, as I expected there to be a larger memory cell pool if these cells 
were truly more effector-like. In addition, mice lacking MFSD2A were producing less IFNγ and 
TNFα under homeostatic memory conditions – this was also the opposite of what I expected of 
true effector-like memory CD8 T cells (Figure 18B and C). 
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Figure 18. MFSD2A-/- phenotyping at homeostatic memory 
Equal numbers of competitively adoptive transferred MFSD2A+/+ CD45.1.2 OT-I and MFSD2A-/- CD45.2 OT-I cells 
were infected with lm-OVA and taken out to memory. A. Frequency of MFSD2A+/+ and MFSD2A-/- splenocytes at 
d40 pi. B. Flow cytometry plots of surface marker expression and intracellular cytokine staining for MFSD2A+/+ and 
MFSD2A-/- cells. For ICS, splenocytes were stimulated ex vivo with OVAp for 6 hrs and golgi stop for the last 3 hrs. 
Data are representative of 3 independent experiments with at least 3 mice per group with p-values calculated using 
student’s t test. 
 
 
 
 
A 
 
B 
 
C 
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Since fewer MFSD2A-/- CD8 T cells were surviving at memory timepoints, I next wanted 
to determine if this was due to a defect in homeostatic proliferation or if cells lacking MFSD2A 
were more apoptotic and dying at a higher rate relative to WT cells. To check if there was a 
proliferation defect, mice were given BrdU injects IP as well as BrdU supplementation into their 
drinking water for two weeks prior to sacrificing to measure BrdU incorporation. Interestingly, 
mice lacking MFSD2A had a highly significant decrease in the amount of actively dividing cells 
as measured by BrdU (Figure 19A). To confirm these findings, the same cells were stained with 
antibodies to cell division marker, Ki-67. MFSD2A-/- cells also had a significant decrease in the 
amount of Ki-67+ cells (Figure 19B). To confirm MFSD2A-/- were not also more apoptotic, 
splenocytes were stained for Annexin V (Figure 19C) and caspase 3 & 7 (data not shown). There 
was no significant difference in either apoptotic marker, and I was able to conclude that cells 
lacking MFSD2A were unable to proliferate normally compared to wild type by memory. 
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Figure 19. MFSD2A-/- has a proliferation defect at memory 
Equal numbers of competitively adoptive transferred MFSD2A+/+ CD45.1.2 OT-I and MFSD2A-/- CD45.2 OT-I cells 
were infected with lm-OVA and taken out to memory. A. Frequency of MFSD2A+/+ and MFSD2A-/- memory 
splenocytes that incorporated BrdU. B. Flow cytometry plots of intracellular Ki-67 staining for MFSD2A+/+ and 
MFSD2A-/- cells. For ICS, splenocytes were stimulated ex vivo with OVAp for 6 hrs and golgi stop for the last 3 hrs. 
C. Annexin V+ CD8 T cells with and without MFSD2A. Samples were run on the cytometer within one hour of 
staining according to the manufacturer’s protocol. Data are representative of 3 independent experiments with at least 
3 mice per group with p-values calculated using student’s t test. 
 
 
Another possible explanation for this phenotype that would not be specific to MFSD2A 
was that when using loss of function mouse models, there was always a chance that the mouse 
line is not 100% backcrossed to the background strain. In order to test this, I sent MFSD2A-/- tail 
samples to Dartmouse (Dartmouth, MS) for a C57BL/6 backcross check screen (data not shown) 
and mice were found to be >95% backcrossed. To reconfirm these findings, I also set up a 
competitive adoptive transfer experiment using littermate control mice to test for late graft 
rejection. Littermate OT-I CD8 T cells did not “disappear” like what was seen with MFSD2A-/- 
cells (Supplemental Figure 4) so we concluded that the phenotype was real and that the loss of 
CD8 T cell homoeostatic proliferation was due to loss of MFSD2A. 
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3.4 MFSD2A-/- RECALL CD8 T CELL RESPONSE 
To test if MFSD2A-/- memory CD8 T cells were capable of producing a successful recall 
response to infection, I again re-challenged these mice with 100,000 CFU of listeria-OVA. I had 
previously performed real-time PCR on wildtype MFSD2A CD8 T cells that were re-challenged 
with listeria-OVA and saw that MFSD2A was upregulated early post-reinfection (Figure 20A). 
This was to be expected since I previously showed that MFSD2A is highly expressed early in the 
primary response (Figure 7A). MFSD2A was significantly upregulated 2.5 days post re-infection, 
in agreement with this hypothesis. MFSD2A-/- memory CD8 T cells were unable to produce a 
robust (or any) recall response (Figure 20B) compared to MFSD2A+/+ cells. By d5 post-
reinfection (which would correspond to the peak recall response), only 3% of OT-I cells lacking 
MFSD2A are still viable, representing a huge reduction in the frequency of MFSD2A-/- cells that 
remain (Figure 20C). Because there were so few cells at this time point, I re-challenged mixed 
bone marrow chimeras to stimulate ex vivo for cytokine production. MFSD2A-/- cells had a 
significant reduction in the frequency of IFNγ+ cells (Figure 20D). Overall, it was concluded that 
without MFSD2A, memory CD8 T cells failed to produce a recall response to infection and that 
this was due to decreased MFSD2A transcripts early post-reinfection. 
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Figure 20. MFSD2A-/- fail to produce a recall response to infection 
Competitive adoptive transfer mice from previous experiments were reinfected with 100,000 CFU lm-OVA and 
analyzed for downstream experiments. A. qPCR analysis for MFSD2A mRNA expression levels of sorted naïve, 
memory, and d2.5 reinfection wildtype OT-I CD8 T cells. B. Frequency of MFSD2A+/+ and MFSD2A-/- cells at 
memory through d19 reinfection with lm-OVA. C. Flow cytometry plot and quantification of specified OT-I cells at 
d5 reinfection with lm-OVA. D. Inflammatory cytokine production in mixed bone marrow chimera mice at d5 
reinfection with lm-OVA following ex vivo stimulation with OVAp for 6 hrs and golgi stop for the final 3 hrs of 
culture. All data except for A is representative of at least 3 independent experiments with 3 animals per group. For 
A, data is representative of 1 experiment with 3 mice per group. P-values were calculated using student’s t test. 
 
 
 
 
D 
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3.5 AIM 1: FUTURE DIRECTIONS 
Based on the above findings, it was clear that there is a negligible role for MFSD2A and 
LPC in CD8 T cell activation but that both molecules become indispensable in CD8 T cell 
memory and recall response to infection. There are other avenues to be explored for MFSD2A 
phenotypical relevance that are worth pursuing. The two with the most potential highlighted 
below. 
3.5.1 MFSD2A AND TISSUE RESIDENT MEMORY CD8 T CELLS 
Tissue resident memory CD8 T cells are noteworthy for being a first-line immunological 
defense in barrier tissues such as the skin and the lung. Studies have shown that Trm cells rely 
heavily on FAO from FFA metabolism and that when the exogenous LCFA transporters FABP4 
and FABP5 are conditionally deleted in T cells that Trm cells (but not Tcm cells) were drastically 
reduced. Since there are numerous lipid transporters that can compensate for each other, it would 
be worthwhile to investigate a role for MFSD2A in Trm cell maintenance.  
Preliminary studies were performed to determine if there may be a link to MFSD2A and 
Trm development. MFSD2A+/+ or -/- OT-I CD8 T cells were adoptively transferred into recipient 
mice and infected with listeria-OVA as described above. On d4, the date considered peak 
bacterial pathogenicity, mice were shaved on their belly and painted with 2,4-dinitro-1-
fluorobenzene (DNFB) to induce contact hypersensitivity in the skin and draw out adoptively 
transferred cells from circulation into the dermis of the skin, i.e., develop OVA-specific Trm that 
could be isolated and quantified by FACS and fluorescent imaging of whole skin mounts. 
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Flow cytometry samples were collected at d7 and d10 pi to gain insight into migration 
patterns of Teff into the skin to see if any obvious disadvantages were present in the MFSD2A-/- 
OT-I CD8 T cells. Interestingly, at d7, there was a decrease in the amount of MFSD2A-/- cells 
within the skin, however, by d10, this relationship had switched and there was actually an 
increased amount of MFSD2A+/+ cells (Fig. 21A). It was worth noting that the size of the skin 
was not measured at these effector timepoints and that skin size is critical in order to calculate an 
actual count of CD8 T cells relative to tissue size rather than going off of a relative cell 
frequency. Noting this disadvantage, skin was quantified and true CD8 Trm cells were measured 
at d45 pi. As expected, there was a decreased amount of CD8 T cells isolated from the skin at 
this timepoint (Fig. 21B), indicating that MFSD2A may be an important lipid transporter 
necessary for Trm development. 
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Figure 21. MFSD2A-/- may have a decreased ability to generate Trm as seen by FACS 
 
MFSD2A+/+ or MFSD2A-/- OT-I CD8 T cells were adoptively transferred into recipient mice and infected with 
listeria-OVA. On d4 pi, mice were treated on the belly with DNFB. A. Quantification of the frequency of transferred 
cells that migrated into the skin at indicated effector day pi.  B. FACS plots (left) showing relative amount of donor 
OT-I CD8 T cells in the skin of recipient mice at d45 pi. CD8 T cells are shown relative to MHCII as a negative 
control. Quantification data (right) is ratio of the CD8+ CD69+ CD103+ cells in the skin over the total amount of 
CD45.2+ cells in the skin by area. Data is representative of 1 independent experiment with 2 animals per group. P-
values were calculated using student’s t test. 
 
 Fluorescent imaging was performed on the above skin samples because microscopy is 
accepted to give a more powerful representation of the cells in the skin compared to flow. Whole 
epidermal sheet mounts were made of skin sample at d45 pi prior to immunofluorescence. 
Surprisingly, more CD8+CD45.1- OT-I cells were found in the mice that received MFSD2A-/- 
OT-I CD8 T cells, indicating that MFSD2A deletion actually creates a larger Trm pool (Fig. 22). 
This data was in contrast to the FACS data in Fig 21. One possible explanation for this was that 
images were of various degrees of clarity due to technical errors and inexperience with the 
immunofluorescent microscope. In any case, flow and imaging data combined show that it may 
be worth pursuing Trm experiments in the future. 
A 
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Figure 22. MFSD2A-/- may not have a decreased ability to generate Trm as seen by IF 
 
MFSD2A+/+ or MFSD2A-/- CD45.2+ CD8 T cells were adoptively transferred into CD45.1+ recipient mice and 
infected with listeria-OVA. On d4 pi, mice were treated on the belly with DNFB. Data is representative of 1 
independent experiment with at least 2 animals per group. Representative images of epidermal sheets from WT and 
KO mice are shown, whereas red indicates CD45.1+ cells, cyan indicates CD8+ cells, and MHCII indicates dendritic 
cells as a positive control. Long autofluorscent strands on images are hair follicles. WT and KO cells were 
considered the MHCII-CD45-CD8+ cells. Quantification of donor to total CD8 T cells was calculated taking the sum 
of amount of MHCII-CD45-CD8+ cells over the total amount of CD8+ cells (the MHCII-CD45+or-CD8+ population). 
Because this is a ratio, data cannot be further analyzed for significance without performing a second independent 
experiment. Data is representative of 1 independent experiment with at least 2 animals per group.   
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3.5.2 MFSD2A AND AUTOIMMUNITY (AND EXPLORING CD4 T CELLS) 
 CD4 T cells have not been explored in this dissertation up until now. Their metabolism 
was outside of the scoop of this work, but it goes without saying that their exogenous LPC 
import by MFSD2A is worth further exploring. It was noted that as Th0 cells differentiate into 
their various T helper subtypes, that metabolism is altered in certain subtypes. One subtype in 
particular, T regulatory (Treg) CD4 T cells, are appreciated for using increased levels of FAO 
metabolism relative to their other CD4 counterparts. Tregs are important for their role as 
immunosuppressers and preventing autoimmunity related autoreactive T cells.  
The mouse model of Treg deletion is known as a “scurfy mouse” due to its scruffy, 
decrepit appearance. If left untreated, these mice die early in age due to autoimmunity. Like CD8 
T cells, it has not been discovered what transporter is importing exogenous lipids in CD4 cells 
and this (like CD8 T cells) represents a knowledge gap in the field of immunometabolism that, if 
found, could be targeted for potential immunotherapy treatment. 
I was able to work with one scurfy mouse to very preliminarily characterize MFSD2A in 
an autoimmunity setting. This mouse was found to have decreased relative levels of MFSD2A in 
its CD4+ T cell population in the lymph nodes (Fig. 23). This phenotype did not repeat when 
looking at the spleen (data not shown), which indicates a need to repeat this experiment with a 
larger sample size to better quantify these data. Still, a role for MFSD2A and LPC in all CD4 
subtypes is worth further exploring and characterizing in future work. 
 
 61 
 
Figure 23. MFSD2A may be decreased in autoimmunity 
Age-matched “scurfy” (Foxp3 del) and WT mice were sacrificed and spleen and lymph nodes were harvested. 
FACS plot (left) shows intracellular staining for MFSD2A gated on the CD4+ cells in the lymph node with 
quantification (right).  Data is representative of 1 independent experiment with 1 animal per group. 
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4.0  SPECIFIC AIM 2 RESULTS 
4.1 MFSD2A-/- AND LPC IMPORT 
Even though I have shown the effect of loss of MFSD2A on CD8 T cells, I wanted to 
relate the lack of memory cell pool and secondary response to infection back to LPC import and 
FAO/FAS in CD8+ T cells. First, in WT mice, I took in vitro activated CD8 T cells and co-
cultured them with 0.1µM Top-Fluor LPC (TF-LPC) for the last 4 hours of a 48 hour 
stimulation. TF-LPC will be taken up by the cells in culture and emit a green fluorescent glow, 
enabling for a way to visualize and quantify relative amounts of LPC import into CD8 T cells. 
One way to visualize this is by making use of Thin Layer Chromatography (TLC). TLC 
separates out extracted lipids as they are drawn up the TLC plate by capillary action. As 
expected, those lipids extracted from activated CD8 T cells show a very robust migration and 
TF-LPC brightness intensity (Fig. 24A) however there was zero fluorescence from naïve CD8 T 
cells, suggesting that naïve cells were not actively taking up TF-LPC in vitro.   
Another way to visualize this was to use confocal microscopy. This technique was useful 
to visualize uptake in live-cells during real time and gives a way to view where in the CD8 T cell 
TF-LPC was migrating to. Interestingly, only in in vitro activated MFSD2A+/+ CD8 T cells TF-
LPC incorporated at the perinuclease (Fig. 24C), suggesting that with loss of MFSD2A I was not 
able to visualize LPC being taken up by the in vitro activated MFSD2A-/- CD8 T cells. This 
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feature was quite striking since the perinuclear space is continuous with the smooth ER – the site 
in the cell where phospholipid synthesis, fatty acid elongation, and fatty acid desaturation all take 
place. These data suggest the LPC species being actively imported into CD8 T cells were being 
used for these processes.  
 
        
 
Figure 24. TF-LPC uptake levels in CD8 T cells with and without MFSD2A 
Biochemical analysis for LPC performed on in vitro (A, B, C) or in vivo activated CD8 T cells cultured for 48 hours 
with anti-CD3 and anti-CD28 (A, B, C) or OVAp (D) and TF-LPC given the last 4 hours of stimulation at 0.1µM. 
A. Thin layer chromatography (TLC) imaging of loading control LPC (C), naïve CD8 T cells (N) or activated (A) 
CD8 T cells co-cultured with LPC and lipids isolated. TLC was ran for 4 hours to allow for separation prior to 
imaging. B. Naïve or Activated CD8 T cells were stained with Hoechst prior to measurement for LPC incorporation 
at the perinucleus out to 80 min. C. FACS plot and quantification of in vitro activated CD8 T cells. D. FACS plot 
and quantification of adoptively transferred MFSD2A+/+ or -/- OT-I CD8 T cells analyzed for TF-LPC uptake via 
flow cytometry. B and D are representative of at least 3 individual experiments with at least 3 mice per group. C is 
representative of 3 experiments with MFSD2A+/+ CD8 T cells and 1 experiment with MFSD2A-/- CD8 T cells. A is 
representative of 2 experiments. Statistical analysis was calculated using Student’s t test or one-way ANOVA. Part 
C microscopy data generated by Callen Wallace and Eric Hyzny. 
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Next, I wanted to characterize LPC uptake yet another way, this time via flow cytometry 
TF-LPC was visible in the FITC channel. I again took in vitro stimulated cells CD8 T cells with 
and without MFSD2A and co-cultured with LPC as described. As expected, only activated 
MFSD2A+/+ CD8 T cells were taking up TF-LPC relative to naïve cells and unstimulated 
controls (Fig 24B). This was also true in memory CD8 T cells in MFSD2A+/+ and MFSD2A-/- 
from adoptive co-transfer experiments that were restimulated for 6 hours with OVAp prior to 
harvest (Fig. 24D), suggesting that LPC import was important for memory CD8 T cells.  It was 
worth noting that in both the in vitro activated and restimulated memory MFSD2A-/- CD8 T cells 
that the level of TF-LPC import was not necessarily at baseline relative to naïve. It was 
hypothesized that this may be due to compensation by alternative lipid transporters such as CD36 
or the FABP family. These studies overall suggest that CD8 T cells were indeed importing LPC 
species and that with loss of MFSD2A, there was a significant decrease in LPC import. 
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Figure 25. TF-LPC uptake in CD8 T cells is an active process 
Wildtype CD8 T cells were pulsed with cell trace violet and then cultured for 72 hours with anti-CD3 and anti-CD28 
with TF-LPC given the last 4 hours of stimulation at 0.1µM. Naïve cells received 10 ng/mL IL-7 for maintenance. 
Quantification histograms detail TF-LPC fluorescence intensity by number of divisions relative to naïve cells. Data 
is representative of 2 individual experiments with at least 3 mice per group. Statistical significance was calculated 
using one-way ANOVA with multiple comparisons. 
 
 
Because stimulated CD8 T cells are much larger in size compared to naïve CD8 T cells 
and because T cells are capable of passive uptake, I wanted to confirm that TF-LPC uptake was 
in fact an active process in CD8 T cells and that the increase in TF-LPC was not just due to the 
activated cells being bigger. To accomplish this, WT CD8 T cells were pulsed with cell trace 
violet (CTV) prior to being stimulated in vitro. CTV labeled and “tracked” cells as they divide as 
a dilution readout. These cells were then given TF-LPC the last 4 hours of culture like previous 
followed by flow cytometry analysis. Indeed, activated CD8 T cells were capable of importing 
TF-LPC regardless of how many divisions the cells have gone through, suggesting that TF-LPC 
was an active process and not dependent on cell size (Fig. 25). 
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Finally, in an effort to better quantify the LPC species imported into activated CD8 T 
cells, I performed a global lipidomic analysis on in vitro activated MFSD2A+/+ or MFSD2A-/- 
CD8 T cells (Fig. 26). This experiment was performed in collaboration with Dr. David Silver’s 
group at Duke-NUS in Singapore. Unfortunately, overall cell counts were quite low and 
biological and technical replicates from each group (naïve samples, activated samples, and naïve 
B6 samples to calibrate the machine) needed to be pooled and then concentrated together in 
order to generate these data, so it was not possible to calculate statistics on these data. The heat 
map, however, showed a trend of decreased PC lipid species in the sample lacking MFSD2A, 
suggesting that with loss of MFSD2A there was also a loss of LPC import into CD8 T cells were 
LPC will then dissociate into PC. The most notable down expressed PC variants are PC 32:0, PC 
38:4, and PC 36:5. There were also notable differences in PE lipid variant (data not shown). It 
was also worth noting that overall, the B6 naïve samples, the naïve WT, and naïve KO samples 
had the largest lipid pool, which was not in agreement with my hypothesis that LPC species were 
only imported into activated CD8 T cells. One such reason for this was that naïve cells do not 
have the rapid turnover for new cellular membrane biogenesis as seen in activated CD8 T cells. 
Another reason may involve use of other lipid transporters used exclusively in the naïve cells. It 
may be worth doing further testing with labeled C13 trace to track lipids in activated and naïve 
CD8 T cells. It could be, particularly in the case of the activated cells, that the lipids are being 
broken down which could explain the overall decreased amount of lipids in the activated CD8 T 
cells. 
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Figure 26. Lipidomic analysis of in vitro activated CD8 T cells 
MFSD2A+/+ and MFSD2A-/- CD8 T cells were activated in vitro as described and then sorted for live cells post-
activation prior to lipid extraction and global lipidomics mass spec. Biological triplicates were pooled to enable 
instrument detection. Naïve B6 are fresh “out of the mouse” CD8 T cells meant to be used for instrument 
calibration. Blue boxes highlight PC species of interest showing a trend of decreased PC species in activated 
WT:KO. Data is represented as mean ± S.E. This data was technically challenging to generate and performed only 
once. Heatmap provided by Dr. David Silver of Duke-NUS, Singapore. 
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4.2 THE METABOLIC OUTCOMES OF UPTAKE OF LPC BY MFSD2A IN 
ACTIVATED T CELLS 
In an effort to better understand how metabolism may be altered in CD8 T cells without 
MFSD2A, I performed Seahorse Flux Bioanalyzer analysis on MFSD2A-/- CD8 T cells.  
Preliminary studies first measured OCR (not shown) and ECAR in 24 hrs in vitro activated CD8 
T cells as readouts of mitochondrial respiration and glycolysis, respectively. CD8 T cells were 
cultured in T Cell Media under optimal conditions. I saw a striking difference in both basal and 
maximal glycolysis (ECAR) rates, with the MFS2A-/- CD8 T cells being more metabolically 
active in both scenarios (Fig. 27A). This was also true, although to a lesser extent, in in vivo 
activated MFSD2A-/- CD8 T cells at d7 pi (Fig. 27B). 
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Figure 27. in vitro and in vivo activated effector CD8 T cell Seahorse analysis 
MitoStress Test analysis was performed using a Seahorse Bioanalyzer on either 24 hour in vitro activated or 7 day in 
vivo activated CD8 T cells with or without MFSD2A. A. In vitro activated CD8 T cells cultured for 24 hours with 
anti-CD3 and anti-CD28 prior to ECAR analysis with basal ECAR quantification. B. Adoptively transferred 
MFSD2A+/+ or -/- OT-I CD8 T cells were sorted at day 7 post listeria infection and ECAR rates were recorded on 
the Seahorse with basal rate quantification. All data is representative of at least 2 individual experiments with at 
least 3 mice per group where samples were pooled prior to Seahorse. Statistical analysis was calculated using 
Student’s t test. 
 
 
Because I saw a more drastic phenotype when MFSD2A-/- mice were taken out to a 
memory time point, I decided to run Seahorse analysis on memory CD8 T cells. Memory CD8 T 
cells should be respiring primary by cellular respiration (OCR) and at relatively low levels as 
they are being homeostatically maintained. However, MFSD2A-/- memory CD8 T cells were 
respiring very robustly compared to MFSD2A+/+ cells (Fig. 28A). They were also using more 
glycolysis compared to WT (Fig. 28A).  Both basal (Fig. 28B) and maximal metabolic rates were 
higher in KO mice, suggesting that they were more metabolically active at memory compared to 
MFSD2A+/+ CD8 T cells.  The spare respiratory capacity (SRC) was also higher in MFSD2A-/- 
A 
 
B 
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(Fig 28B), meaning they should be able to produce more ATP if need be. Overall, these findings 
suggest that MFSD2A-/- CD8 T cells were more metabolically active compared to MFSD2A+/+ 
CD8 T cells, and that these findings were at higher intensity at memory. 
 
 
 
Figure 28. Memory time point CD8 T cell Seahorse analysis 
MitoStress Test analysis was performed using a Seahorse Bioanalyzer on adoptively transferred MFSD2A+/+ or -/- 
OT-I CD8 T cells that were sorted at memory (d45 pi) post listeria infection and pooled prior to Seahorse. A Raw 
run files of OCR and ECAR. B. Quantification of maximum OCR rate, maximum ECAR rate, and SRC between 
MFSD2A+/+ and MFSD2A-/- memory OT-I CD8 T cells. of All data is representative of 2 individual experiments 
with at least 3 mice per group where samples were pooled prior to Seahorse. Statistical analysis was calculated using 
Student’s t test. 
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4.2.1 GLUT1 MAY COLOCALIZE WITH LPC IN CD8 T CELLS 
There were reports that GLUT1 co-localized with MFSD2A at the BBB to actively 
transport glucose into the brain. In addition to this, others found that GLUT1 transported glucose 
into activated CD4 T cells. Because of these findings, I wanted to investigate if GLUT1 levels 
were altered with loss of MFDS2A and if this could result in further metabolic disfunction within 
the CD8 T cell. It was hypothesized that if GLUT1 and MFSD2A co-localized on effector CD8 
T cells after activation, that if one was lost at the TCR immunological synapse, that it may 
impact the other (in this case, loss of MFSD2A impacting GLUT1) and that there will be overall 
decreased import of exogenous metabolites. MFSD2A+/+ and -/- CD8 T cells were stimulated in 
vitro for 48 hours prior to flow cytometry staining for GLUT1. Indeed, with loss of MFSD2A 
there appeared to be a decrease in the amount of intracellular GLUT1 (Fig. 29A) and net 
GLUT1, the difference between extra and intracellular GLUT1 (data not shown). In addition to 
these data, there were no differences in GLUT1 mRNA (Fig. 29B), suggesting that loss of 
MFSD2A may only effect GLUT1 on the protein level and not transcriptionally. These findings 
suggest that, as in the brain, MFSD2A colocalized with GLUT1 and that when MFSD2A was 
lost, GLUT1 expression was also decreased which could result in further metabolic dysfunction 
and decreased ability to import exogenous metabolites in activated CD8 T cells. 
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Figure 29. GLUT1 protein and RNA expression data with loss of MFSD2A 
MFSD2A+/+ and MFSD2A-/- CD8 T cells were stimulated in vitro for 48 hrs with αCD3αCD28 prior to analysis for 
GLUT1 protein and RNA. A. Protein GLUT1 levels are shown relative to live CD8 T cells (left panel) and by 
histogram (middle panel) with quantification (right panel). B. Real-time PCR expression data for GLUT1. All data is 
representative of 2 individual experiments with at least 1-3 mice per group. Statistical analysis was calculated using 
Student’s t test. 
4.3 THE GENETIC CONTROL OF MFSD2A AND LPC ON CD8 T CELLS 
Because exogenous LCFAs imported into the mitochondria are metabolized into acetyl-
CoA and the fate of some of this acetyl-CoA will eventually become a key component for 
histone acetylation, I was interested in the epigenetic control loss of MFSD2A had on histone 
modification, particularly histone acetylation. After numerous experiments including western 
blotting for H3K27ac (Fig. 30A) that gave inconsistent results and investigating chromatin 
accessibility at the IFNγ locus (a gene dysregulated with loss of MFSD2A as illustrated in Aim 
1)(Fig. 30B), I concluded that histone acetylation was probably unperturbed in MFSD2A KO. 
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The next logical step was to determine what genes were altered with loss of MFSD2A: Was there 
pathway dysregulation? Were there changes in transcription factor expression or in genes 
required for glycolysis and cellular respiration? 
 
 
Figure 30. Epigenetic regulation by MFSD2A 
A. MFSD2A+/+ and MFSD2A-/- CD8 T cells were stimulated in vitro for 48 hrs with αCD3αCD28 prior to analysis 
for H3K27ac protein by Western blot. Acetylated H3K27 was normalized by examining total H3 input B. 
MFSD2A+/+ and MFSD2A-/- effector CD8 T cells were harvested from competitive adoptive transferred recipient 
mice at d7 pi and sorted for purity prior to lysis, chromatin digestion, and genomic qPCR analysis of samples at the 
IFNγ locus. Fold enrichment (FE) was calculated by taking the difference of Ct values between digested chromatin 
samples and non-digested controls. All data is representative of 1-2 individual experiments with at least 2 mice per 
group. Statistical analysis was calculated using Student’s t test. 
 
To answer these questions, I performed RNA-sequencing on adoptively transferred 
MFSD2A+/+ and -/- OT-I CD8 T cells from mice infected with listeria and taken out to d40 pi. 
There were numerous changes in transcription (Fig. 31A) however I did not find one master gene 
to connect the dots between phenotype and function in the MFSD2A-/-.. Still, some genes of 
interest were differentially expressed (Fig. 31B), including downregulation of interferon 
inducible proteins GM4955 and PYDC4 as well as increased expression of genes related to co-
stimulatory inhibition and inhibitory receptors, CD244 and KLRA9, respectively. Interestingly, 
growth hormone was also slightly increased in MFSD2A-/-, suggestive of a novel way to increase 
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glucose and FFA concentration. Overall, the majority of transcripts appeared to be upregulated 
genes in MFSD2A-/-. I hypothesized this was due to the greater metabolic demand that was seen 
by Seahorse in the KO cells, inducing overall higher levels of gene transcription at homeostatic 
memory compared to MFSD2A+/+ CD8 T cells. 
 
 
 
Figure 31. RNA-sequencing results summary from memory CD8 T cells 
Memory MFSD2A+/+ and MFSD2A-/- OT-I CD8 T cells were sorted prior to RNA sequencing. A. Heat Map was 
generated in CLC Genomics 11. B. Genes of notable function with high fold change were picked out and further 
examined for function as it may relate to MFSD2A. Data are representative of one experiment with 2 mice per 
group. 
 
 
To make sense of the sequencing data generated, I decided to investigate pathway 
analysis and try to piece together where MFSD2A and lipid metabolism fit into my phenotype in 
Aim 1. I used Ingenuity Pathway Analysis (IPA) software to accomplish this. IPA has a specific 
‘metabolomics for IPA’ pathway program that generated a genetic trail based on known 
  KO1     KO2      WT1      WT2 
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metabolic pathways and regulators. I performed the metabolomics analysis using the table of 
differentially expressed genes with p<0.05. Interesting, the sequencing data, including one of the 
top gene hits CD244, linked back to the ERK1/2 signaling pathway (Fig. 32). Although this 
pathway does not directly link to LCFA metabolism, it does have potential regulator control over 
cell survival, cell cycle progression, and CD8 T cell proliferation – all hallmarks of the memory 
CD8 T cell phenotype without MFSD2A as shown in Aim 1.  ERK activation was not 
investigated further, but may be an avenue for future experimental work linking changes in T cell 
signaling pathways to loss of MFSD2A. 
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Figure 32. Metabolomics pathway analysis for memory CD8 T cells 
Memory MFSD2A+/+ and MFSD2A-/- OT-I CD8 T cells were sorted prior to RNA sequencing. A. Heat Map was 
generated in CLC Genomics 11. B. Genes of notable function with high fold change were picked out and further 
examined for function as it may relate to MFSD2A. Data are representative of one experiment with 2 mice per 
group. 
 
Finally, recent reports illustrated that MFSD2A negatively regulates fatty acid synthesis 
(FAS) in the brain. Fatty acid and cholesterol synthesis in itself is regulated by two proteins, 
SREBP1 and SREBP2. With loss of MFSD2A in the brain, there was an increase in SREBP1 and 
SREBP2 protein in the tissue, with the idea that FAS and cholesterol synthesis (SREBP1 and 
SREBP2, respectively) are being increased to compensate for loss of exogenous LPC import. 
When MFSD2A+/+ and -/- CD8 T cells were activated in vitro and analyzed for mRNA expression 
of SREBP1 by real-time PCR, there was elevated levels of SREBP1 after 48 hours in vitro 
activation (Fig. 33A). In addition to this, when competitive adoptive transfer mice were taken out 
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to a memory timepoint and restimulated ex vivo with OVAp, there was again increased levels of 
SREBP1 expression in MFSD2A-/- cells (Fig. 33B), suggesting that this increased level of FAS is 
also seen in MFSD2A-/- memory CD8 T cells re-challenged with antigen. These data suggested 
that like in the brain, MFSD2A deficient CD8 T cells were able to compensate for lack of LPC 
import by upregulating genes related to FAS and generate lipids de novo.  
Overall, MFSD2A deficient CD8 T cells showed an altered gene transcription, including 
possible alterations in signaling pathways and compensatory genes related to FAS, but future 
studies would need to be performed in order to confirm these findings. 
 
 
 
 
Figure 33. SREBP1 is elevated in MFSD2A deficient CD8 T cells 
A. MFSD2A+/+ and MFSD2A-/- CD8 T cells were enriched and stimulated in vitro for 48 hrs with αCD3αCD28 or 
10 ng/mL IL-7 (unstimulated) prior to sorting for live cells and downstream RNA processing. B. MFSD2A+/+ and 
MFSD2A-/- CD8 T cells were sorted from competitive adoptive transferred mice that were taken out to a memory 
time point (d40 pi) and either restimulated ex vivo with OVAp or media alone for 48 hours prior to sorting for live 
cells and downstream RNA processing. For A, data are representative of two pooled experiments with 1 mouse per 
group per experiment and p-value calculation using Student’s t-test. For B, data is representative of one experiment 
with pooled memory cells from 3-5 mice per group.  
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4.4 AIM 2: FUTURE DIRECTIONS 
Aim 2 has explored how MFSD2A is importing LPC in CD8 T cells, where the LPC 
migrates to once within the cell, the metabolic consequences of loss of MFSD2A on CD8 T cells, 
and dysregulation of gene expression. Out of all of the above, the gene expression data – 
especially the RNA-sequencing data – is the most perplexing. One idea as to why may be found 
above in Fig. 18A. MFSD2A expression was close to basal at memory and goes back up early 
(d2.5) post-reinfection with listeria. Sequencing samples were not stimulated ex vivo or 
reinfected, so it is within reason to think that more genes would be induced upon reinfection  and 
restimulation based on the mentioned MFSD2A qPCR expression data. With that in mind, RNA-
sequencing restimulated memory CD8 T cells is an excellent direction to pursue. The other 
potential pitfall with Aim 2 study design may be found within the mice themselves. 
4.4.1 MFSD2A IN THE FASTED STATE 
 It has previously been published by collaborators Silver et al that MFSD2A was a fasting-
induced gene that was induced by PPARα and glucagon signaling. For all experiments in this 
document, mice were not fasted nor were they on a special low fat/high carbohydrate diet. Is it 
possible that, if MSFD2A-/- mice were on a special diet or fasted the night before harvest, would 
the phenotype in these mice be the same or would it be more extreme? Similarly, was there error 
in these current data based on whether a mouse ate within hours of harvest compared to another 
mouse that was voluntarily fasting in its cage? These are real variables that need to be taken into 
 79 
consideration with the work in Aim 2, especially all data related to metabolism of these mice as 
well as gene expression data. 
Another element to this fasting paradox is the in vitro data. CD8 T cells were incubated 
for the indicated amount of time under ideal culture conditions in TCM. What if rather than 
TCM the system had been challenged? If CD8 T cells were cultured in a nutrient poor media for 
48 hours, they would not have exogenous metabolites already in place in their media to readily 
uptake. It would be worth repeating any and all introductory in vitro experiments using a low 
glucose or serum free media and observe how MFSD2A deficient CD8 T cells compare to their 
wildtype counterparts under non-ideal culturing conditions. 
 
 
 80 
5.0  DISCUSSION 
By investigating phenotype and functional differences in CD8 T cells, this dissertation 
has given critical evidence in support of a role of MFSD2A in CD8 T cells. MFSD2A expression 
was significantly increased early post in vitro CD8 T cell activation. These data formulated the 
initial hypothesis of this work suggesting that MFSD2A and import of exogenous LCFA by LPC 
was necessary during the initial CD8 T effector response following infection with listeria, and 
that MFSD2A remained critical for memory CD8 T cell formation and maintenance due to 
memory cells’ indispensable need for a bank of biosynthetic precursors and TAG storage 
generated during the primary effector response to help memory cells quickly respond to 
secondary antigen challenge. Surprisingly, MFSD2A and LPC loss created very little change in 
the primary effector response, with only subtle differences in KLRG1 and CD127 surface marker 
expression on those cells apparently pre-determined to become memory CD8 T cells. Once 
experimental mice reached a true memory time point, the effects of loss of MFSD2A and LPC 
became more striking. MFSD2A deficient CD8 T cells had a homeostatic proliferation defect by 
the time they reached memory, and when presented with antigen rechallenge, these cells were 
unable to produce a secondary response to infection compared to their WT counterparts. 
In what was perhaps counterintuitive, MFSD2A-/- memory CD8 T cells were more 
metabolically active: they were more glycolytic, had increased cellular respiration, and a 
significantly higher spare respiratory capacity. These data were indicative of the higher basal 
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rates necessary by MFSD2A deficient CD8 T cells in order to perform an increased amount of de 
novo fatty acid synthesis. This potential increase in FAS is one way that KO cells have 
developed compensatory effects to counteract the loss of exogenous lipid import. Additional data 
supporting this increase in FAS was higher relative expression levels of the FAS regulating gene 
SREBP1 in restimulated memory MFSD2A-/- CD8 T cells. These data were supported by recent 
reports showing that when FAS was inhibited early in the CD4 T cell effector response there was 
a decreased frequency of cells in the CD4 memory cell pool[91]. These higher metabolic rates 
could also be a reason that I see decreased overall amounts of MFSD2A deficit memory CD8 T 
cells as it was within reason to hypothesize that eventually these cells ‘run out of gas’, are unable 
to sustain homeostatic proliferation, and die. 
It is fair to say that other compensatory measures may be at play. Numerous exogenous 
lipid transporters have been identified in various immune cell types. FABP4 and FABP5 were 
already mentioned in reference to tissue resident memory CD8 T cell development. There were 
no significant differences in these genes in my RNA sequencing data but this may be due to not 
performing sequencing on more energetically demanding restimulated memory CD8 T cells (see 
future directions for Aim 2). Another important lipid transporter is CD36. CD36 was identified 
as a critical lipid transporter and signaling molecule in macrophages, where it was shown to be a 
mandatory signal for macrophages to bind to oxidized low density lipoprotein (OxLDL) and 
contribute to the formation of foam cells in atherosclerosis[158]. Data on CD36 in CD8 T cells is 
inconclusive, including pilot experiments conducted in relation to this work, but it is fair to 
suggest that CD36 and/or members of the FABP family may have increased expression levels in 
MFSD2A-/- CD8 T cells to pick up the slack for lack of MFSD2A and that this form of 
compensation may be way MFSD2A loss was detrimental to the CD8 T cell but not 100% lethal. 
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Looking into any potential compensatory lipid transporter mechanisms in CD8 T cells with loss 
of MFSD2A is a critical component to this work that will need to be investigated in the future. 
As noted in the above text, the phenotype associated with loss of MFSD2A was most 
striking when using the competitive adoptive transfer approach rather than directly infecting WT 
and KO mice or when performing signal adoptive transfer experiments where mice received 
either WT or KO OT-I CD8 T cells rather than both. These data suggested that loss of MFSD2A 
in CD8 T cells may not be overly terminal to CD8 T cells alone, but rather that the phenotype 
that was seen at least in due part to the MSFD2A deficient CD8 T cells being “less fit” compared 
to their WT counterparts. Why would loss of a lipid transporter make CD8 T cells less fit in a 
competitive environment? The answer may be found within the animals themselves. During 
competition, cells are under pressure to survive (i.e., survival of the fittest) and to capture all 
available nutrients within their environment. Those CD8 T cells that contain MFSD2A were able 
to import exogenous LPC species with ease to bank their metabolites needed in times of 
memory. However, MFSD2A deficient CD8 T cells need to expend more energy and synthesize 
their own nutrients, wasting time and energy to do so while their WT counterparts focused on 
cell survival. 
What does all of this mean for humans? The few families with known mutations in 
MFSD2A suffer from microcephaly-like syndromes but have very little known about their 
immunopathology. Due to these patients being so rare and so sick, their immune system remains 
to be investigated for a potential phenotype. As shown in the results section, MFSD2A is known 
to be conserved through evolution and in my hands there appears to be upregulation of MFSD2A 
in human CD8 T effector cells in the PBL, similar to what has now been shown in mouse. 
Although blood has not been analyzed in these patients, it is hypothesized that they would have 
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increased blood plasma LPC levels compared to healthy, age matched controls and that these 
patients would have a reduced memory CD8 T cell pool with an inability to use CD8 T cell 
memory to prevent recurrent infections. 
Could MFSD2A ever have clinical relevance? Public health organizations such as the 
AHA and WHO recognize DHA as an important component to a healthy lifestyle. Along with 
that, a walk to the local grocery or health store is full of supplements advertising the importance 
of LCFAs in a healthy diet for everything from improved cognition to their anti-inflammatory 
properties. I have experimentally shown that MFSD2A is expressed early in infection and does 
not become of critical importance until immunological memory has been reached. Thus, how 
fatty acids are imported into CD8 T cells has a clinical relevancy for determining how vaccines 
can be better designed and how diet can be controlled to better fight infection. If, for example it 
is possible to better control infection by obtaining more dietary LCFAs? Vaccines may also be 
able to benefit from a smart design targeting LPC. For instance, by creating small molecule 
therapeutics to target LPC and boost the immune response from vaccination, leading to a more 
robust treatment. Similarly, vaccines of engineered memory CD8 T cells have proven promising 
for treating tumors. MFSD2A is critical to memory CD8 T cell maintenance. If tumor-specific 
memory CD8 T cells with bioengineered MFSD2A overexpression were injected into the tumor 
site, they may be more capable of destroying tumors than tumor-specific memory CD8 T cells 
alone. 
Taken together, the data within this dissertation used a combination of molecular and 
biochemical approaches to prove that there is a role for MFSD2A and LPC CD8 T cells in 
response to infection. This document is the first of its kind to show a purpose for LCFA import 
into CD8 T cells and how, when lost, it can have disastrous consequences on the secondary 
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immune response to infection. It is only a start for what MFSD2A and LPC may be critical for in 
the immune response to infection, and further investigation needs to be examined. Future 
directions below each Aim critically analyze possible directions to take this project, including 
where and how MFSD2A can be relevant in the clinic and in overall public health. 
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APPENDIX A:  LIST OF ABBREVIATIONS 
AHA: American Heart Association 
APC: antigen presenting cell 
BAT: brown adipose tissue 
BrdU: bromodeoxyuridine 
CD: cluster of differentiation 
CPT1: carnitine palmitoyltransferase I 
CTV: cell trace violet 
DAMPS: danger-associated molecular patterns 
DAG: diacylglyerol 
DC: dendritic cell 
DHA: docosahexaenoic acid 
DNFB: 2,4-dinitro-1-fluorobenzene 
EDTA: ethlenediaminetetraacetic acid 
ER: endoplasmic reticulum 
FABP: fatty acid binding protein 
FACS: fluorescence-activated cell sorting 
FAO: fatty acid oxidation 
FAS: fatty acid synthesis 
FBS: fetal bovine serum 
FCS: fetal calf serum 
FE: fold enrichment 
FFA: free fatty acids 
IF: immunofluorescence 
IP: intraperitoneal 
IV: intraveneously 
KO: knockout 
LM: listeria monocytogenes 
LPC: lysophosphatidylcholine 
MFSD2A: major facilitator superfamily domin containing 2a 
MHCI: major histocompatibility complex class I 
MHCII: major histocompatibility complex class II 
MPEC: memory precursor effector cell 
OxLDL: oxidized low density lipoprotein 
PA: phosphatidic acid 
PAMPS: pattern-associated molecular patterns 
PBS: phosphate buffered saline 
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PBL: peripheral blood lymphocytes 
PC: phophatidylcholine 
PCR: polymerase chain reaction 
qPCR: real-time polymerase chain reaction 
Pi: post infection 
PRR: pattern recognition receptors 
RO: retrooribitally 
SRC: spare respiratory capacity 
SREBP: sterol regulatory element-binding protein 
Teff: T effector cell 
Trm: tissue resident memory T cells 
Tmem: T memory cell 
TAG: triacylglycerol 
TCA cycle: tricarboxylic acid cycle 
TCM: T cell media 
TCR: T cell receptor 
TNF: tumor necrosis factor 
TF-LPC: TopFluor-lysophosphatidylcholine 
UC: ulcerative colitis 
WB: western blot 
WHO: World Health Organization 
WT: wildtype 
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APPENDIX B:  LIST OF PCR PRIMER SEQUENCES AND REAL-TIME PCR 
TAQMAN ASSAY PROBES 
Genotyping PCR 
 
MFSD2A:  
F: ACG TTG TCG CCA CCA TCA TCA CC  
R: CTT AAT AGT GAC ACT ACG AGG TTC CGG G 
 
CD4 Cre: 
F: GCG GTC TGG CAG TAA AAA CTA TC 
R: GTG AAA CAG CATTGC TGT CAC TT 
 
OT-I 
F: AAG GTG GAG AGA GAV AAA GGA 
R: CCA GTG CAT GCA TAC CTC AG 
 
 
Real-Time PCR 
 
GLUT1 (Slc2a1) 
F: ATG GAT CCC AGC AGC AAG 
R: CCA GTG TTA TAG CCG AAC TGC 
 
IFNγ genomic primers 
IFNγ Exon1 F: TAT AGC TGC CAT CGG CTG AC 
IFNγ Exon 1 R: GAA AGT CTG AAT AAC TGT TTT 
 
Taqman Assay Probe IDs 
 
MFSD2A: Mm01192208_m1 
SREBP1: Mm00550338_m1 
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APPENDIX C:  LIST OF ANTIBODIES 
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APPENDIX D:  DIAGRAM OF IN VIVO MODEL 
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APPENDIX E:  SUPPLEMENTAL FIGURES 
 
 
 
 
 
Supplemental Figure 1. MFSD2A-/- has a decreased CD8 memory precursor cell pool 
Mice received equal amounts of MFSD2A+/+ and MFSD2A-/- OT-I CD8 T cells prior to infection with 5000 CFUs 
lm-OVA. Time course of effector response showing frequency of KLRG1loCD127hi MFSD2A+/+ and MFSD2A-/- 
memory precursor cells at indicated time point (left). Quantification of frequency of KLRG1loCD127hi MFSD2A+/+ 
and MFSD2A-/- cells at d10 pi (right). All data is from blood. Data are representative of at least 3 independent 
experiments with at least 3 mice per group with p-values calculated using student’s t. 
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Supplemental Figure 2. MFSD2A-/- has similar effector response in mice directly infected with listeria 
MFSD2A+/+ and MFSD2A-/- mice were directly infected with 5000 CFUs lm-OVA to measure the endogenous 
response. OVA specific CD8 effector CD8 T cells were measured using OVA tetramer. Time course of effector 
response showing frequency of OVA tetramer positive cells at indicated effector time point (left). Quantification of 
frequency of OVA tetramer positive MFSD2A+/+ and MFSD2A-/- CD8 T cells at memory (right). All data is from 
blood. Data are representative of at least 3 independent experiments with at least 3 mice per group with p-values 
calculated using student’s t. No data was significant. 
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Supplemental Figure 3. Endogenous response at memory and secondary infection in MFSD2A-/- mice   
A. Time course of effector response showing frequency of OVA tetramer positive cells in MFSD2A+/+ and 
MFSD2A-/- mice previously infected with listeria that received a high dose (100,000 CFU) rechallenge with listeria. 
at indicated effector time point. B and C: MFSD2A+/+ and MFSD2A-/- bone marrow was depleted of lymphocytes 
and then injected in a 50:50 ratio to irradiated CD45.1 recipient mice. Mice were given 8 weeks to recover. Mice 
were then directly infected with 5000 CFUs lm-OVA to measure the endogenous response. OVA specific CD8 
effector CD8 T cells were measured using OVA tetramer. B. FACS plot and quantification of frequency of OVA 
tetramer positive MFSD2A+/+ and MFSD2A-/- CD8 T cells at memory. C. Mixed bone marrow chimera mice were 
reinfected with 100,000 CFU lm-OVA. FACS and quantification are from d6 peak post reinfection. All data is from 
blood. Data are representative of at least 3 independent experiments with at least 3 mice per group with p-values 
calculated using student’s t. For A, no data was statistically significant. 
 
 
 
A 
 
B 
 
C 
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Supplemental Figure 4. MFSD2A littermate OT-I CD8 T cells do not reject at memory 
MFSD2A+/+ CD45.1.2 and MFSD2A+/+ CD45.2 OT-I CD8 T or MFSD2A+/+ CD45.1.2 and MFSD2A-/- CD45.2 OT-I 
CD8 T were competitively adoptively transferred in a 50:50 ratio to CD45.1 recipient mice. Mice were then infected 
with 5000 CFUs lm-OVA. FACS plot showing littermate OT-I (left) and MFSD2A-/- OT-I (right) as the CD45.2 
single positive population d40 pi. All data is from blood. Data are representative of 1 independent experiment with 
at least 3 mice per group. 
 
d40 post-infection 
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